<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" open-status="O" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Front Pharmacol</journal-id><journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id><journal-title-group><journal-title>Frontiers in Pharmacology</journal-title></journal-title-group><issn pub-type="epub">1663-9812</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5103413</article-id><article-id pub-id-type="doi">10.3389/fphar.2016.00423</article-id><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="48038" pm="."><plain>Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Zhi-xiang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/377517/overview"/></contrib><contrib contrib-type="author"><name><surname>Mo</surname><given-names>Jingxin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="author-notes" rid="fn002"><sup>†</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/275058/overview"/></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Guixian</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shu</surname><given-names>Gang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Hua-lin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="author-notes" rid="fn001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/284569/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Pharmacy, College of Veterinary Medicine, Sichuan Agricultural University</institution><country>Chengdu, China</country></aff><aff id="aff2"><sup>2</sup><institution>Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University</institution><country>Guangzhou, China</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Histology and Embryology, Zhongshan School of Medicine, Sun Yat-sen University</institution><country>Guangzhou, China</country></aff><author-notes><fn fn-type="edited-by"><p><text><SENT sid="48039" pm="."><plain>Edited by: Alexandre Arcaro, University of Bern, Switzerland </plain></SENT>
</text></p></fn><fn fn-type="edited-by"><p><text><SENT sid="48040" pm="."><plain>Reviewed by: Jacques Barbet, Arronax GIP, France; José Mordoh, Fundación Instituto Leloir, Argentina </plain></SENT>
</text></p></fn><corresp id="fn001">*Correspondence: <italic>Hua-lin Fu, <email xlink:type="simple">fuhl2005@sohu.com</email> Wei Zhao, <email xlink:type="simple">zhaowei23@mail.sysu.edu.cn</email></italic></corresp><fn fn-type="other" id="fn002"><p><text><SENT sid="48041" pm="."><plain>†These authors have contributed equally to this work. </plain></SENT>
</text></p></fn><fn fn-type="other" id="fn003"><p><text><SENT sid="48042" pm="."><plain>This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>7</volume><elocation-id>423</elocation-id><history><date date-type="received"><day>10</day><month>8</month><year>2016</year></date><date date-type="accepted"><day>25</day><month>10</month><year>2016</year></date></history><permissions><copyright-statement>Copyright © 2016 Yuan, Mo, Zhao, Shu, Fu and Zhao.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Yuan, Mo, Zhao, Shu, Fu and Zhao</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="48043" pm="."><plain>Renal cell carcinoma (RCC) is a common form of urologic tumor that originates from the highly heterogeneous epithelium of renal tubules. </plain></SENT>
<SENT sid="48044" pm="."><plain>Over the last decade, targeting therapies to renal cancer cells have transformed clinical care for RCC. </plain></SENT>
<SENT sid="48045" pm="."><plain>Recently, it was proposed that renal cancer stem cells (CSCs) isolated from renal carcinomas were responsible for driving tumor growth and resistance to conventional chemotherapy and radiotherapy, according to the theory of CSCs; this has provided the rationale for therapies targeting this aggressive cell population. </plain></SENT>
<SENT sid="48046" pm="."><plain>Precise identification of renal CSC populations and the complete cell hierarchy will accurately inform characterization of disease subtypes. </plain></SENT>
<SENT sid="48047" pm="."><plain>This will ultimately contribute to more personalized and targeted therapies. </plain></SENT>
<SENT sid="48048" pm="."><plain>Here, we summarize potential targeting strategies for renal cancer cells and renal CSCs, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors (mTOR), interleukins, CSC marker inhibitors, bone morphogenetic protein-2, antibody drug conjugates, and nanomedicine. </plain></SENT>
<SENT sid="48049" pm="."><plain>In conclusion, targeting therapies for RCC represent new directions for exploration and clinical investigation and they plant a seed of hope for advanced clinical care. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>renal cell carcinoma</kwd><kwd>renal cancer stem cells</kwd><kwd>targeting strategies</kwd><kwd>renal cancer</kwd><kwd>surface markers</kwd></kwd-group></SecTag><funding-group><award-group><funding-source id="cn001">National Natural Science Foundation of China<named-content content-type="fundref-id">10.13039/501100001809</named-content></funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="0"/><equation-count count="0"/><ref-count count="143"/><page-count count="15"/><word-count count="0"/></counts></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="48050" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="48051" pm="."><plain>Renal cell carcinoma (RCC) is not a single entity, but rather comprises a population of tumors that originate from the highly heterogeneous epithelium of renal tubules. </plain></SENT>
<SENT sid="48052" pm="."><plain>According to the Heidelberg classification of renal cell tumors, histologic subtypes of RCC include clear cell adenocarcinoma, which is the most common form of RCC, chromophobe collecting duct carcinoma, papillary carcinoma, and unclassified carcinomas (Kavacs et al., 1997). </plain></SENT>
<SENT sid="48053" pm="."><plain>Among urologic tumors, RCC has the highest cancer-specific mortality rate, and the 5-year survival rate for patients with metastatic disease is only 12% (Siegel et al., 2015). </plain></SENT>
<SENT sid="48054" pm="."><plain>In addition, RCC accounts for approximately 3.8% of all adult human malignancies, with an annually increasing incidence (Koul et al., 2011). </plain></SENT>
<SENT sid="48055" pm="."><plain>Chemotherapy is one of the principal modes of cancer treatment; however, its effectiveness is limited by drug resistance. </plain></SENT>
<SENT sid="48056" pm="."><plain>Moreover, RCC is also resistant to radiation, and weakly sensitive to immunotherapeutic agents, such as interleukin (IL)-12 and interferon (INF)-α. </plain></SENT>
<SENT sid="48057" pm="."><plain>Tumor recurrence occurs in 40% of patients after curative surgical resection (Koul et al., 2011). </plain></SENT>
<SENT sid="48058" pm="."><plain>To date, RCC is still a tumor of unpredictable presentation and poor clinical outcome. </plain></SENT>
</text></p><p><text><SENT sid="48059" pm="."><plain>Cancer stem cells (CSCs) are a small population of cancer cells responsible for resistance to radiation and chemotherapy. </plain></SENT>
<SENT sid="48060" pm="."><plain>There are numerous mechanisms that may explain chemo-radiation resistance of CSC, including their assumed quiescence, high drug eﬄux capacity, residing in hypoxic niches, and the up-regulation of DNA damage response and repair genes (Shukrun et al., 2014). </plain></SENT>
<SENT sid="48061" pm="."><plain>They are also responsible for metastasis, tumor development, disease progression, and disease recurrence. </plain></SENT>
<SENT sid="48062" pm="."><plain>They are characterized by an extraordinary capacity for unlimited cell division and maintenance of the stem cell pool in the tumor. </plain></SENT>
<SENT sid="48063" pm="."><plain>They keep dividing until they build terminally differentiated, specialized cells due to unlimited self-renewal and multipotency toward heterogeneous progeny (Visvader and Lindeman, 2008; Clevers, 2011). </plain></SENT>
<SENT sid="48064" pm="."><plain>There is accumulating evidence that selective targeting of CSCs is possible and that CSCs can be selectively eradicated to improve the survival and quality-of-life in cancer patients (Yilmaz et al., 2006; Smith et al., 2010). </plain></SENT>
</text></p><p><text><SENT sid="48065" pm="."><plain>There is common consent that renal CSCs have tumorigenic ability and that they are resistant to chemo- and radio-therapy, providing the rationale for therapies targeting this aggressive cell population. </plain></SENT>
<SENT sid="48066" pm="."><plain>The development of personalized treatment strategies is supported by comprehensive molecular analyses of RCC (Gerlinger et al., 2012; Bielecka et al., 2014) and pharmacogenomics studies of putative CSCs (Crea et al., 2011). </plain></SENT>
<SENT sid="48067" pm="."><plain>In terms of selective markers for CSCs in clear cell RCC (ccRCC), CD105, a prominent marker, can distinguish a rare subpopulation of cells that exhibit CSC properties (Bussolati et al., 2008, 2011). </plain></SENT>
<SENT sid="48068" pm="."><plain>CD133, also known as prominin-1, is a transmembrane glycoprotein that has been investigated as another putative marker of renal progenitor cells in the adult human kidney; it appears to be non-tumorigenic and it is expressed in resident adult kidney progenitors cells (Bruno et al., 2006). </plain></SENT>
<SENT sid="48069" pm="."><plain>The side population (SP), which can be identified using a Hoechst 33342 dye eﬄux assay, can also express putative CSC markers, but it has not been reliably demonstrated that SP also displays CSC properties (Addla et al., 2008). </plain></SENT>
</text></p><p><text><SENT sid="48070" pm="."><plain>Specific CSC markers could represent valuable tools for targeting these cells with drugs or immunotoxins. </plain></SENT>
<SENT sid="48071" pm="."><plain>Investigation of intracellular pathways and genetic abnormalities may lead to the development of efficient therapeutic strategies targeting renal CSCs (Bussolati et al., 2013). </plain></SENT>
<SENT sid="48072" pm="."><plain>The development of a slew of rationally designed targeted therapies that inhibit vascular endothelial growth factor (VEGF) receptor and mammalian target of rapamycin (mTOR) pathways has contributed to the systemic management of RCC. </plain></SENT>
<SENT sid="48073" pm="."><plain>Furthermore, molecular targeting nanomedicine-based approaches, which can control drug delivery and release more efficiently, can effectively inhibit multiple types of CSCs. </plain></SENT>
<SENT sid="48074" pm="."><plain>In this review, the author summarizes the potential targeting strategies underlying tyrosine kinase inhibitors, mTOR inhibitors, interleukins, CSC marker inhibitors, bone morphogenetic protein-2 (BMP-2), antibody drug conjugates (ADCs), and nanomedicine that can target renal cancer cells and renal CSCs to treat RCC more efficiently. </plain></SENT>
</text></p></sec></SecTag><sec><title><text><SENT sid="48075" pm="."><plain>Normal Renal Stem Cells </plain></SENT>
</text></title><p><text><SENT sid="48076" pm="."><plain>According to the “hierarchical” theory, the three most common RCC histologic subtypes (undifferentiated, clear-cell, papillary carcinomas) may arise from the stem cell pool of the adult kidney or from the deriving progenitors. </plain></SENT>
<SENT sid="48077" pm="."><plain>Whereas the Wilm’s tumor may arise from the embryonic renal stem cell compartment (Bussolati et al., 2011). </plain></SENT>
<SENT sid="48078" pm="."><plain>To isolate and characterize of renal stem cells, several methods have been attempted. </plain></SENT>
<SENT sid="48079" pm="."><plain>These include pulse-chase labeling of slow cycling cells, dye exclusion assay, FACS/magnetic bead separation by stem cell surface markers, and selective culture conditions for renal dissociated tissue (Gupta et al., 2006; Sagrinati et al., 2006; Gupta and Rosenberg, 2008; Ronconi et al., 2009). </plain></SENT>
<SENT sid="48080" pm="."><plain>The isolated cells exhibited multipotent differentiation capacity in vitro. </plain></SENT>
<SENT sid="48081" pm="."><plain>Importantly, they can integrate into injured renal tubules. </plain></SENT>
<SENT sid="48082" pm="."><plain>The parietal epithelium of Bowman’s capsule, which give rise to both podocytes and tubules, has been suggested harbor intrarenal stem cells. </plain></SENT>
<SENT sid="48083" pm="."><plain>In addition, multipotent CD133+/CD24+ stem cells have been further isolated from the Bowman’s capsule. </plain></SENT>
<SENT sid="48084" pm="."><plain>CD133+ renal progenitor cells have been characterized in the renal cortex from the tubule/interstitium (Sagrinati et al., 2006; Lindgren et al., 2011). Humphreys et al. (2008) evaluated the degree of involvement by extratubular cells during renal regeneration. </plain></SENT>
<SENT sid="48085" pm="."><plain>Their results demonstrated that the proliferating intratubular epithelium accounts for tubular regeneration (Humphreys et al., 2008). </plain></SENT>
<SENT sid="48086" pm="."><plain>However, the putative connection between renal stem cells and renal carcinomas is still not clarified due to the unequivocal understandings of the renal stem cell. </plain></SENT>
<SENT sid="48087" pm="."><plain>For example, numerous technical limitations hindered the efforts for the isolation and characterization of renal stem cells; and there are different stem cell subpopulations with restricted differentiation potential in kidneys. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48088" pm="."><plain>Renal Cancer Stem Cell Markers </plain></SENT>
</text></title><p><text><SENT sid="48089" pm="."><plain>Multiple studies have been designed to isolate and characterize the CSC population in RCC using stem cell markers, which are considered targets in CSC therapy. </plain></SENT>
<SENT sid="48090" pm="."><plain>A better understanding of stem cell markers and the related signaling pathways that contribute to tumor progression and metastasis is important for the development of strategies for CSC-targeting treatments. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48091" pm="."><plain>Stem Cell Surface Markers in Renal CSCs </plain></SENT>
</text></title><p><text><SENT sid="48092" pm="."><plain>CD105, also called endoglin, is a receptor for transforming growth factor-β (TGF-β) and is expressed on the cell surface. </plain></SENT>
<SENT sid="48093" pm="."><plain>It regulates cellular proliferation, differentiation, and migration, and is therefore important for angiogenesis (Dallas et al., 2008). </plain></SENT>
<SENT sid="48094" pm="."><plain>By magnetically sorting cells in RCC specimens, Bussolati et al. (2008) separated a subpopulation of cells expressing the mesenchymal marker CD105. </plain></SENT>
<SENT sid="48095" pm="."><plain>This finding is consistent with the mesenchymal origin of the kidney and the mesenchymal phenotype of stem cells found in normal rodent kidney as well as in the human embryo; these cells represented less than 10% of the total tumor mass (Bussolati et al., 2008). </plain></SENT>
<SENT sid="48096" pm="."><plain>They could differentiate into epithelial cells both in vitro and in vivo. In vivo, CD105-positive (CD105+) cells could display the tumor-initiating activity that as few as 100 cells could generate transplantable tumors. In vitro they could differentiate into both epithelial and endothelial cells. </plain></SENT>
<SENT sid="48097" pm="."><plain>These results indicated that the CD105+ cells may originate from resident renal stem cells with mesenchymal characteristics. </plain></SENT>
<SENT sid="48098" pm="."><plain>In addition, other studies have reported that CD105+ cells are present in the established RCC cell lines 786-O, 769-P, ACHN, Caki-1, Caki-2, SMKTR2, SMKTR3, and RCC-6 (Khan et al., 2012, 2013) and that there is no relationship between CD105 and gender, age, cell type, or tumor size (Sandlund et al., 2006). </plain></SENT>
<SENT sid="48099" pm="."><plain>More recently, a CSC differentiation strategy test was conducted on CD105+ CSCs to aid in their isolation from human renal carcinomas. </plain></SENT>
<SENT sid="48100" pm="."><plain>CD105+ CSCs differentiated into cells that expressed epithelial markers (E-cadherin and pan-cytokeratin) when they were treated with recombinant human IL-15 (rhIL-15) at a concentration of 10 pg/mL. </plain></SENT>
<SENT sid="48101" pm="."><plain>Compared with severe combined immunodeficiency (SCID) mice that were injected with untreated CD105+ CSCs, SCID mice with IL-15-treated CSCs demonstrated significantly higher levels of apoptosis in differentiated epithelial cells following treatment with vinblastine or paclitaxel (Azzi et al., 2011). </plain></SENT>
<SENT sid="48102" pm="."><plain>In patients, high CD105 levels are associated with higher tumor stage and CD105 is a crucial indicator of clinical outcome. </plain></SENT>
<SENT sid="48103" pm="."><plain>Therefore, further investigation of potential therapeutic targets is warranted. </plain></SENT>
</text></p><p><text><SENT sid="48104" pm="."><plain>CD133, a five transmembrane domain glycoprotein, belongs to the prominin family. </plain></SENT>
<SENT sid="48105" pm="."><plain>It contains two large extracellular and two small intracellular loops (Grosse-Gehling et al., 2013). </plain></SENT>
<SENT sid="48106" pm="."><plain>Currently, it serves as a useful marker for the isolation and characterization of various types of stem and progenitor cells in human tissues. </plain></SENT>
<SENT sid="48107" pm="."><plain>Using a specific monoclonal antibody, human CD133 was first isolated from hematopoietic stem cells (HSCs) which consisted of various kinds of stem/progenitor cells and differentiated cells. </plain></SENT>
<SENT sid="48108" pm="."><plain>The CD133+ cell population can influence tumor vascularization and angiogenesis, and it is also expressed in normal adult human kidney cells (Bussolati et al., 2005). Zhang et al. (2013) observed that CD133 expression was associated with stage, histological type, tumor location, and tumor grade. Bruno et al. (2006) demonstrated that CD133+ progenitor cells derived from human RCC contributed to tumor vascularization. </plain></SENT>
<SENT sid="48109" pm="."><plain>High expression of CD133 is associated with a macro-/micro-cystic pattern, non-metastatic disease, and non-sarcomatoid changes (Kim et al., 2011). </plain></SENT>
<SENT sid="48110" pm="."><plain>CD133 may have a role in risk stratification; its overexpression was associated with longer survival in patients with ccRCC. </plain></SENT>
<SENT sid="48111" pm="."><plain>On the other hand, low CD133 expression is an independent predictor of poor disease-specific survival (DSS) and progression-free survival (PFS) (Costa et al., 2012). </plain></SENT>
<SENT sid="48112" pm="."><plain>Additionally, CD133 may be involved in both epithelial and endothelial differentiation in vitro and in vivo. </plain></SENT>
<SENT sid="48113" pm="."><plain>However, CD133+ cells were not able to induce carcinoma development after subcutaneous injection into SCID mice, indicating non-tumorigenic potential. </plain></SENT>
<SENT sid="48114" pm="."><plain>This result is in contrast with the idea that renal CSCs arise from renal progenitors expressing the CD133 marker (Bussolati et al., 2011). </plain></SENT>
<SENT sid="48115" pm="."><plain>Interestingly, injection of CD133+ cells with the RCC cell line K1 into SCID mice would lead to significant tumor growth and progression. </plain></SENT>
<SENT sid="48116" pm="."><plain>Inside the tumor, the newly formed vessels expressed both human CD31 and human HLA class I. The resultant tumor vessels via the differentiation of CD133+ progenitor cells plus K1 cells was later confirmed by fluorescence in situ hybridization for human origin of chromosome X (Bruno et al., 2006). </plain></SENT>
<SENT sid="48118" pm="."><plain>However, clinical significance of CD133 expression in human RCC is inconsistent. </plain></SENT>
<SENT sid="48119" pm="."><plain>In addition, no study showed that CD133 can serve as a therapeutic target for renal cancer or renal CSCs because of its wide expression in kidney progenitor cells probably. </plain></SENT>
<SENT sid="48120" pm="."><plain>But many papers have reported targeting CD133+ cells therapy for other cancers. </plain></SENT>
<SENT sid="48121" pm="."><plain>More recently, Qi et al. (2016) loaded chemotherapeutic antitumor drugs and small interfering RNA (siRNA) against CD133+ into mesoporous silica nanoparticles (MSNPs) with thermo/pH-coupling sensitivity and site-specificity. </plain></SENT>
<SENT sid="48122" pm="."><plain>These MSNPs successfully inhibited its growth in vivo in a laryngeal cancer mouse model by eliminating CD133+ cells (Qi et al., 2016). </plain></SENT>
</text></p><p><text><SENT sid="48123" pm="."><plain>CD44, a single-chain transmembrane glycoprotein, binds primarily to the extracellular glycosaminoglycan hyaluronan, an adhesion molecule for the extracellular matrix (Ponta et al., 2003; Hiraga et al., 2013). </plain></SENT>
<SENT sid="48124" pm="."><plain>This interaction is considered a signaling platform for integrating cellular microenvironmental cues with growth factor and cytokine signals. </plain></SENT>
<SENT sid="48125" pm="."><plain>Moreover, Debeb et al. (2010) described CD44+/CD24- cells with several CSC features in the human embryonic cell line 293T. </plain></SENT>
<SENT sid="48126" pm="."><plain>Although CD44+ human carcinomas are very resistant to therapy and highly malignant, there is still some debate on the role of CD44 in CSCs. </plain></SENT>
<SENT sid="48127" pm="."><plain>Undoubtedly, metastatic potential is improved by the expression of CD44, and metastatic properties are often linked to CSCs (Toole, 2009; Zhang et al., 2013). </plain></SENT>
<SENT sid="48128" pm="."><plain>Furthermore, CD44+/CD24- cells in three-dimensional (3D) spheres were reported to be resistant to radio- and chemo-therapy (Debeb et al., 2010). </plain></SENT>
<SENT sid="48129" pm="."><plain>In another report, Lim et al. (2008) suggested that CD44 expression in RCC could be used to inform the appropriate therapy and provide useful prognostic information in both primary and metastatic RCC. </plain></SENT>
<SENT sid="48130" pm="."><plain>Meanwhile, a meta-analysis of the literature showed that CD44 was a poor prognostic marker for 5-year overall survival and that high CD44 expression levels were associated with high Fuhrman grade and recurrence (Li et al., 2015). </plain></SENT>
<SENT sid="48131" pm="."><plain>A new study proposed by Ma et al. (2016) proposed a possible mechanism for CD44 upregulation. </plain></SENT>
<SENT sid="48132" pm="."><plain>They found that a third of the tumor samples analyzed expressed CD44, and that while CD44 expression was not associated with clinical outcome, it was associated with a high density of tumor-associated macrophages (Ma et al., 2016). </plain></SENT>
</text></p><p><text><SENT sid="48133" pm="."><plain>CXCR4 is a 352-amino acid rhodopsin-like G-protein coupled receptor (GPCR) which binds selectively to the CXC chemokine stromal cell-derived factor-1 (SDF-1, also known as CXCL12). </plain></SENT>
<SENT sid="48134" pm="."><plain>CXCR4 is expressed on all kinds of tissues and organs and normal stem cells. </plain></SENT>
<SENT sid="48135" pm="."><plain>Therefore, it is one of the best researched chemokine receptors (Weitzenfeld and Ben-Baruch, 2014). </plain></SENT>
<SENT sid="48136" pm="."><plain>The expression of CXCR4 has a significant negative predictive value on PFS in patients treated with IFN-α (Li et al., 2011). </plain></SENT>
<SENT sid="48137" pm="."><plain>Low or absent CXCR4 expression is predictive of a good response to sunitinib therapy, while CXCR4 expression is associated with a poor response to sunitinib in metastatic ccRCC (D’ Alterio et al., 2012). </plain></SENT>
<SENT sid="48138" pm="."><plain>Furthermore, the CXCL12-CXCR4 signaling axis plays an important role in the homing of normal stem cells (Lapidot and Kollet, 2002). </plain></SENT>
<SENT sid="48139" pm="."><plain>This CXCL12-CXCR4 axis is involved in the trafficking/metastasis of CSCs to various organs when CXCR4 is expressed; CXCR4 is also highly expressed in the lymph nodes, lungs, liver, and bone (Kucia et al., 2005; Mukherjee and Zhao, 2013). Gassenmaier et al. (2013) compared the capacity of two RCC cell lines, RCC-26 and RCC-53, to form spheres in vitro and to establish tumors in vivo, and observed that CXCR4 was present only in the more tumorigenic RCC-53 cell line (Gassenmaier et al., 2013). Micucci et al. (2015) recently reported that the self-renewing ability of CXCR4+ spheres was enhanced before the upregulation of hypoxia-inducible factor 2α (HIF-2α) in the RCC cell lines Caki-1, Caki-2, 786-O, and 769-P. </plain></SENT>
<SENT sid="48140" pm="."><plain>Knockdown of HIF-2α abolished CXCR4+ sphere formation and expression, and inhibition of HIF-2α abrogated tumor growth in vivo, proving that HIF-2α activation plays an important role in CSC expansion. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48141" pm="."><plain>Intracellular Markers in Renal CSCs </plain></SENT>
</text></title><p><text><SENT sid="48142" pm="."><plain>Cancer stem cells are likely derived from differentiated cancer cells through various mechanisms, including cellular interactions, tumor niche signals, and epithelial to mesenchymal transition (EMT) (Schieber and Chandel, 2013; Pattabiraman and Weinberg, 2014). </plain></SENT>
<SENT sid="48143" pm="."><plain>EMT is a highly conserved cell process involved in normal embryogenesis and tissue repair (Liu and Fan, 2015). </plain></SENT>
<SENT sid="48144" pm="."><plain>Recently, numerous studies have shown that EMT plays a momentous role in tumor progression. </plain></SENT>
<SENT sid="48145" pm="."><plain>Through EMT, tumor cells can obtain stem cell-like characteristics, through the acquisition of mesenchymal properties. </plain></SENT>
<SENT sid="48146" pm="."><plain>The results of accumulating studies have indicated that a promising link exists between EMT and the CSC phenotype. Lichner et al. (2015) reported that isolated RCC spheres displayed CSC-like properties that were linked to the TGF-β-EMT axis. </plain></SENT>
<SENT sid="48147" pm="."><plain>Additionally, recent research has suggested that EMT can be artificially induced during the culture of the RCC cell lines ACHN and 786-O, enriching their stem cell-like characteristics (Liu and Fan, 2015). </plain></SENT>
<SENT sid="48148" pm="."><plain>ACHN and 786-O cells treated with 50 ng/ml tumor necrosis factor-α lost their epithelial morphology and acquired a mesenchymal appearance with increased expression of mesenchymal protein markers such as vimentin, slug, and ZEB1. </plain></SENT>
</text></p><p><text><SENT sid="48149" pm="."><plain>Li et al. (2014) proposed a method to reverse the EMT process and inhibit CSC-like features in RCC. </plain></SENT>
<SENT sid="48150" pm="."><plain>According to their results, honokiol extract isolated from magnolia bark – a multifunctional antiangiogenic and natural antitumor agent – can simultaneously abrogate proliferation, reverse EMT (as determined by an increase in epithelial markers and a decrease in mesenchymal markers), and significantly inhibit the CSC properties of RCC cells in vivo (tumorigenicity) and in vitro (sphere formation, invasion/migration, SP) (Fried and Arbiser, 2009; Li et al., 2014; Weygant et al., 2015). </plain></SENT>
<SENT sid="48151" pm="."><plain>Of note, a recent study found that high expression of the PIK3R1 protein was associated with RCC progression and metastasis (Lin et al., 2015). </plain></SENT>
<SENT sid="48152" pm="."><plain>A PIK3R1 knockout functional study demonstrated that PIK3R1 plays a crucial role in RCC cell proliferation and migration; maintenance of a mesenchymal morphology; and the incremental expression of EMT-related factors in vitro (Lin et al., 2015). </plain></SENT>
<SENT sid="48153" pm="."><plain>By analyzing data in The Cancer Genome Atlas’ Kidney Renal Clear Cell Carcinoma (TCGA KIRC) dataset, Weygant et al. (2015) demonstrated that doublecortin-like kinase 1 (DCLK1) regulates EMT and maintains stemness features; DCLK1 is overexpressed in RCC tumors regardless of disease stage. </plain></SENT>
<SENT sid="48154" pm="."><plain>In primary RCC-Caki-2 cells, silencing of the DCLK1 gene using DCLK1 siRNA resulted not only in decreased expression of EMT transcription factors (SNAI1, SNAI2, TWIST1, ZEB1, and Vimentin), but also reduced expression of the pluripotency and stemness factors MYC, Nanog, Oct-4, Sox-2, and aldehyde dehydrogenase (ALDH) 1A1 (Weygant et al., 2015). </plain></SENT>
<SENT sid="48155" pm="."><plain>These results corroborated the finding that DCLK1 knockdown can inhibit the invasive and metastatic ability of RCC cells. </plain></SENT>
</text></p><p><text><SENT sid="48156" pm="."><plain>Recently, SP cells from an RCC cell line were genetically modified to knock out DnaJ (Hsp40) homolog, subfamily B, member 8 (DNAJB8) and examine its function in the tumorigenicity of RCC (Yamashita et al., 2016). </plain></SENT>
<SENT sid="48157" pm="."><plain>Compared with non-SP RCC cells, the SP is distinguishable by increased sphere-forming ability in vitro, enhanced proliferative potential, and greater expression levels of β-catenin, Sonic Hedgehog, Notch, and Pax-2 stem cell markers. </plain></SENT>
<SENT sid="48158" pm="."><plain>Furthermore, the SP had an abundance of ALDH-positive cells, suggesting that ALDH enzymatic activity may be associated with the SP (Ueda et al., 2013). </plain></SENT>
<SENT sid="48159" pm="."><plain>DNAJB8 knockout cells displayed a decreased ratio of SP to non-SP cells and reduced sphere-forming ability, indicating that DNAJB8 contributes to CSC-like phenotype of RCC (Nishizawa et al., 2012). </plain></SENT>
<SENT sid="48160" pm="."><plain>This study also demonstrated that the overexpression of DNAJB8 increased the proportion of SP cells, boosted tumor-initiating ability, and enhanced the expression of stem cell markers (Nishizawa et al., 2012). </plain></SENT>
<SENT sid="48161" pm="."><plain>Furthermore, western blots and immunostains of SP cells have shown that these cells express DNAJB8 protein, indicating stem cell-like phenotypes. </plain></SENT>
<SENT sid="48162" pm="."><plain>In DNA vaccination experiments, DNAJB8, as a potential marker of RCC CSCs, was considered as an immunotherapeutic target. </plain></SENT>
</text></p><p><text><SENT sid="48163" pm="."><plain>MicroRNAs (miRNAs) have been described in various cancers, including prostate cancer, glioblastoma, and breast cancer (Liu and Tang, 2011; Shimono et al., 2015). </plain></SENT>
<SENT sid="48164" pm="."><plain>They are non-coding, small, single-stranded RNA molecules, that play a significant role in posttranscriptional gene regulation and are essential in sustaining normal pluripotent embryonic stem cells in mice (Melton et al., 2010). </plain></SENT>
<SENT sid="48165" pm="."><plain>Analysis of the effect of miR-17 on RCC spheres with cancer stem-like properties revealed that spheres from ACHN and Caki-1 cell lines demonstrated greater tumorigenic capacity and elevated expression of mesenchymal markers and stem cell in vivo (Lichner et al., 2015). </plain></SENT>
<SENT sid="48166" pm="."><plain>miR-17 overexpression hindered sphere formation by modulating the TGF-β-EMT axis (Petrocca et al., 2008). </plain></SENT>
<SENT sid="48167" pm="."><plain>Interestingly, miR-17 inhibition led to increased colony formation in ACHN and Caki-1 cell lines, which demonstrated that miR-17 could regulate the self-renewing properties of the cells; inhibition also enhanced expression of mesenchymal markers and cancer stem markers (Giron-Michel et al., 2012). </plain></SENT>
<SENT sid="48168" pm="."><plain>In summary, miR-17 belongs to a carcinogenic miRNA cluster necessary for development and homeostasis (Concepcion et al., 2012). </plain></SENT>
<SENT sid="48169" pm="."><plain>Further research on miRNAs in RCC tumor promotion, therapy resistance, metastasis, progression and relapse will contribute to a better understanding of RCC tumor biology (Liu and Tang, 2011). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48170" pm="."><plain>Potential Targeting Strategies </plain></SENT>
</text></title><p><text><SENT sid="48171" pm="."><plain>In the view of the resistance to chemo- and radio-therapies (Lyakhovich and Lleonart, 2016) and the weak response to immunotherapeutic agents (Di Lorenzo et al., 2010) demonstrated by RCC, more attention has been paid to the development of potential approaches to target renal CSCs. </plain></SENT>
<SENT sid="48172" pm="."><plain>Over the past several years, more and more encouraging data have demonstrated proof of principle that targeting CSCs could block the pathways associated with drug resistance, disease progression, aggressiveness, and metastasis, and may lead to complete and durable regression; this could improve treatment outcomes for patients with RCC and affect prognosis (Figure 1) (Sehl et al., 2009; Smith et al., 2010; Azzi et al., 2011). </plain></SENT>
<SENT sid="48173" pm="."><plain>In particular, strategies that can target markers expressed on the cell surface or disrupt specific signaling pathways are considered ideal targeting strategies for CSCs. </plain></SENT>
<SENT sid="48174" pm="."><plain>Identification of potential targets in the renal CSC microenvironment or nanocarriers for delivery of active compounds may also result in the development of efficient strategies for the elimination of CSCs. </plain></SENT>
<SENT sid="48175" pm="."><plain>Potential targeting strategies for renal cancer cell and renal CSCs are summarized in the next section. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>FIGURE 1</label><caption><p><text><SENT sid="48176" pm="."><plain>Conventional therapy and targeting therapy for cancer stem cells (CSCs) in renal cell carcinoma (RCC). Conventional therapy in RCC can reduce tumor size. </plain></SENT>
<SENT sid="48177" pm="."><plain>However, CSCs are resistant to conventional therapies and induce tumor relapse through self-renewal and division. </plain></SENT>
<SENT sid="48178" pm="."><plain>Targeted therapy for CSCs provides a new direction to eradicate the tumor. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-07-00423-g001"/></fig></SecTag></sec><sec><title><text><SENT sid="48179" pm="."><plain>Tyrosine Kinase Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="48180" pm="."><plain>Tyrosine kinase signaling is a unique biochemical mechanism utilized by intra- and inter-cellular communication pathways in metazoans. </plain></SENT>
<SENT sid="48181" pm="."><plain>Abnormal tyrosine kinase signaling leads to various cancers, as well as other diseases (Levitzki, 2013). </plain></SENT>
<SENT sid="48182" pm="."><plain>Tyrosine kinase inhibitors (TKIs) are novel therapies that target specific cellular signaling pathways by primarily blocking tyrosine kinase receptors that are involved in the progression of several tumors, including RCC (Eichelberg et al., 2008; Albiges et al., 2012). </plain></SENT>
<SENT sid="48183" pm="."><plain>By inhibiting the activity of growth factor receptors, in particular, VEGF receptor, platelet-derived growth factor (PDGF) receptor, and the stem cell factor c-KIT receptor, TKIs can significantly affect tumor angiogenesis and/or tumor cell proliferation. </plain></SENT>
<SENT sid="48184" pm="."><plain>Sunitinib and sorafenib, commercially available TKIs, are associated with good treatment response and are tolerable in RCC patients. </plain></SENT>
<SENT sid="48185" pm="."><plain>However, severe side effects including cardiotoxicity, hypothyroidism, hypertension, fatigue, hair depigmentation, hand-foot syndrome, and gastrointestinal perforation have been observed (Cohen and Oudard, 2012; Sternberg et al., 2015; Jang et al., 2016). </plain></SENT>
<SENT sid="48186" pm="."><plain>Importantly, Czarnecka et al. (2015b) recently reported that a much more severe side effect, chronic myeloid leukemia (CML), developed in some patients with ccRCC during TKI treatment. </plain></SENT>
<SENT sid="48187" pm="."><plain>The authors described a potential molecular mechanism of action of TKIs on bone marrow cells that may be responsible, in part, for development of CML (Czarnecka et al., 2015b). </plain></SENT>
</text></p><p><text><SENT sid="48188" pm="."><plain>Several pathways involved in oncogenesis are blocked by TKIs, including pathways in growth, survival, proliferation, and, most importantly, differentiation and apoptosis. </plain></SENT>
<SENT sid="48189" pm="."><plain>However, TKIs have not been considered a primary therapy for CSCs because they lack sufficient selectivity for this peculiar cell type. </plain></SENT>
<SENT sid="48190" pm="."><plain>Poor selectivity is also the main reason for many of the side effects of TKIs. </plain></SENT>
<SENT sid="48191" pm="."><plain>Recent studies have demonstrated that TKIs can decrease the proliferation rate of renal CSCs, but that the efficacy of the growth inhibition was limited by hypoxic conditions and 3D intratumoral cell–cell interactions (Czarnecka et al., 2016). </plain></SENT>
<SENT sid="48192" pm="."><plain>More evidence is needed to prove that TKIs have an inhibitory effect on renal CSCs and to delineate their mechanism of action in this cell type. </plain></SENT>
<SENT sid="48193" pm="."><plain>Thus, a better understanding of this effect will lead to more successful therapies for RCC. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48194" pm="."><plain>mTOR Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="48195" pm="."><plain>Mammalian target of rapamycin inhibitors, an important therapeutic target for RCC, permits protein translation that drives cell growth, proliferation, and the production of angiogenic growth factors including HIF-1, VEGF, and PDGF. </plain></SENT>
<SENT sid="48196" pm="."><plain>In RCC, mTOR is stimulated by a VEGF-induced phosphorylation cascade, which involves PI3K and Akt (Czarnecka et al., 2015a; Xia and Xu, 2015). </plain></SENT>
<SENT sid="48197" pm="."><plain>Activation of the mTOR pathway leads to translation of proteins involved in cell cycle progression and HIF-1α expression, which is associated with RCC pathogenesis. </plain></SENT>
<SENT sid="48198" pm="."><plain>On the other hand, mTOR inhibitors whose mechanism of action is distinct from that of the TKIs mentioned above, halt tumor cell growth and angiogenesis by down-regulating HIF expression and blocking proliferation and survival signals downstream of the VEGF receptor (Kornakiewicz et al., 2014; Liu et al., 2016). </plain></SENT>
<SENT sid="48199" pm="."><plain>Temsirolimus and everolimus are orally administered mTOR inhibitors used for targeted therapy in metastatic renal cell carcinoma (mRCC). </plain></SENT>
<SENT sid="48200" pm="."><plain>Clinical trials in patients with mRCC showed that treatment with temsirolimus or everolimus prolonged PFS relative to the placebo in patients with mRCC that had progressed on other targeted therapies (Motzer et al., 2008; Negrier, 2008). </plain></SENT>
<SENT sid="48201" pm="."><plain>To date, it is unknown if mTOR inhibitors may prove to be selective enough for renal CSCs and research on their selectivity is ongoing. </plain></SENT>
<SENT sid="48202" pm="."><plain>Interestingly, some clues can be found from a number of recent studies on mTOR inhibitors that eradicated the CSC populations in nasopharyngeal carcinoma, colon cancer, and glioblastoma multiforme, among other cancers (Francipane and Lagasse, 2013; Sami and Karsy, 2013; Kolev et al., 2015; Yang et al., 2015), which may indicate future directions for designing novel drugs targeting mTOR for renal CSCs. </plain></SENT>
</text></p><p><text><SENT sid="48203" pm="."><plain>The emerging perspective for mTOR inhibitors in RCC treatment involves combination therapies targeting both renal cancer cells and renal CSCs. </plain></SENT>
<SENT sid="48204" pm="."><plain>This approach requires analysis of multiple overlapping signaling networks to carefully preselect suitable molecular targets on these cells (Czarnecka et al., 2015a). </plain></SENT>
<SENT sid="48205" pm="."><plain>However, the researchers are facing a greater challenge for trying to find new molecular targets since current knowledge on the systems biology of renal cancer cells and renal CSCs are far from enough. </plain></SENT>
<SENT sid="48206" pm="."><plain>Therefore, attempts have been made to develop a combination treatment consisting of mTOR inhibitors and TKIs. </plain></SENT>
<SENT sid="48207" pm="."><plain>A combination of everolimus and sorafenib was used in the treatment of mRCC; this combination had acceptable toxicity levels and demonstrated antitumor activity in previously untreated patients with mRCC (Amato et al., 2012). </plain></SENT>
<SENT sid="48208" pm="."><plain>Another combination consisting of temsirolimus plus bevacizumab, an mTOR inhibitor, and a VEGF inhibitor, showed encouraging evidence in a Phase 1 trial for the treatment of mRCC. </plain></SENT>
<SENT sid="48209" pm="."><plain>However, the results of the Phase 2/3 trial did not show a sufficient improvement in efficiency (Rini et al., 2014; Jobard et al., 2015). </plain></SENT>
<SENT sid="48210" pm="."><plain>Additional combinations using mTOR inhibitors together with other targeted agents can more effectively inhibit mTOR and/or block signaling in multiple pathways, such as the PI3K/Akt/mTOR and Ras/Raf/MEK/Erk pathways (Asati et al., 2016; McKay et al., 2016). </plain></SENT>
</text></p><p><text><SENT sid="48211" pm="."><plain>Indeed, it remains to be seen if novel combination therapies using mTOR inhibitors can target both renal cancer cells and renal CSCs. </plain></SENT>
<SENT sid="48212" pm="."><plain>Several studies have successfully used combination treatments to target CSCs in other cancers. </plain></SENT>
<SENT sid="48213" pm="."><plain>A combination treatment in glioblastoma multiforme uses differentiating agents with mTOR pathway inhibitors to target CSCs, thereby targeting the ERK1/2 pathway. </plain></SENT>
<SENT sid="48214" pm="."><plain>This underscores the importance of including differentiating agents along with inhibitors of mTOR pathways in the treatment of glioblastoma multiforme (Friedman et al., 2013). </plain></SENT>
<SENT sid="48215" pm="."><plain>Similar studies confirmed that mTOR inhibitors combined with other agents represented promising therapeutic strategies to eradicate CSCs in breast cancer, liver cancer, and pancreatic cancer (Zhu et al., 2012; Gedaly et al., 2013; Sharma et al., 2015). </plain></SENT>
</text></p><p><text><SENT sid="48216" pm="."><plain>Beyond temsirolimus and everolimus, there have been a slew of second generation mTOR inhibitors, such as mTORC1/mTORC2 inhibitors and mTOR/PI3K dual inhibitors, that have shown promising activity in pre-clinical studies or have entered clinical trials (Vilar et al., 2011; Zhang et al., 2011). </plain></SENT>
<SENT sid="48217" pm="."><plain>According to the NIH database1, over 50 clinical trials, ongoing or completed, proposed to apply mTOR inhibitors for the treatment of RCC. </plain></SENT>
<SENT sid="48218" pm="."><plain>Regardless of the potential effect of novel mTOR inhibitors on CSCs, it may be necessary to combine them with other drugs to ensure an antiangiogenic effect. </plain></SENT>
<SENT sid="48219" pm="."><plain>Combinatorial control of cell signaling still seems to be more successful than monotherapy. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48220" pm="."><plain>Interleukins </plain></SENT>
</text></title><p><text><SENT sid="48221" pm="."><plain>The interleukins act as ligands and regulate many physiologic and pathophysiologic processes by binding to their receptors and activating or inhibiting several intracellular pathways. </plain></SENT>
<SENT sid="48222" pm="."><plain>This has led to the investigation of these pathways as potential therapeutic targets. </plain></SENT>
<SENT sid="48223" pm="."><plain>Interleukins-1, -2,-3, -4, -6, -11, -12, -15, -18, and -21 have been tested in the clinic with variable rates of success and failure as cancer therapeutics (Aulitzky et al., 1994; Dranoff, 2004). </plain></SENT>
<SENT sid="48224" pm="."><plain>IL-2-based immunotherapy has been approved by the FDA and is the standard therapy for advanced RCC, even though poor response and severe toxicity can occur in some cases (Di Lorenzo et al., 2010). </plain></SENT>
<SENT sid="48225" pm="."><plain>The response rate with IL-2 treatment ranges from 7 to 27%. </plain></SENT>
<SENT sid="48226" pm="."><plain>The best response was achieved in patients with favorable Motzer criteria, ccRCC, and lung metastases only. </plain></SENT>
<SENT sid="48227" pm="."><plain>Long-term complete responders have been reported with high-dose bolus IL-2 regimens in ccRCC (Ljungberg et al., 2010). </plain></SENT>
</text></p><p><text><SENT sid="48228" pm="."><plain>IL-15 exhibits a therapeutic index superior to that of IL-2, and is commonly used in renal cancer treatment (Steel et al., 2012; Waldmann, 2014). </plain></SENT>
<SENT sid="48229" pm="."><plain>Although some of the biological properties of IL-15 overlap with those of IL-2, such as the activation of natural killer (NK) cells and CD8 T cells, IL-15 is not associated with capillary leak syndrome or activation-induced cell death, nor does it have a major effect on the number of functional regulatory T cells (Waldmann et al., 2011). </plain></SENT>
<SENT sid="48230" pm="."><plain>Systemic administration of rhIL-15 showed less toxic effects than IL-2, indicating that multiple daily infusions of rhIL-15 could be administered to patients with metastatic malignancies (Munger et al., 1995; Waldmann et al., 2011). </plain></SENT>
<SENT sid="48231" pm="."><plain>Recently, IL-15 was shown to induce differentiation of CD105+ renal CSCs isolated from human renal carcinomas (Azzi et al., 2011). </plain></SENT>
<SENT sid="48232" pm="."><plain>Based on previous studies that had shown that IL-15 acted as a survival factor in renal tubular epithelial cells via autocrine-paracrine loops, the authors identified IL-15 as a potential candidate (Shinozaki et al., 2002). </plain></SENT>
<SENT sid="48233" pm="."><plain>Other studies have shown that IL-15 upregulates E-cadherin expression through γc chain signaling pathway and blocks EMT in renal tubular epithelial cells (Figure 2) (Giron-Michel et al., 2012, 2013). Azzi et al. (2011) demonstrated that IL-15 can induce the stable epithelial differentiation of renal CD105+ CSCs, thereby generating a differentiated non-tumorigenic cell population that is more sensitive to the chemotherapeutic drugs vinblastine and paclitaxel, compared with the parental CSCs. </plain></SENT>
<SENT sid="48234" pm="."><plain>RCC cells do not secrete IL-15, suggesting that the loss of intratumoral IL-15 secretion could be a protection mechanism for CSC stemness (Trinder et al., 1999; Azzi et al., 2011). </plain></SENT>
<SENT sid="48235" pm="."><plain>Finally, self-renewal along with tumor sphere-forming ability was blocked in renal CSCs treated with IL-15, indicating the potential utility of IL-15 as a differentiation therapy in RCC. </plain></SENT>
<SENT sid="48236" pm="."><plain>These observations support that IL-15 is a key factor directing the epithelial differentiation of renal CSCs. </plain></SENT>
<SENT sid="48237" pm="."><plain>Moreover IL-15 therapy meets the criteria of CSC targeting treatment strategy: depletion of CSCs pool and generation of differentiated non-tumorigenic cells with increased sensitivity to chemotherapeutic drugs. Azzi et al. (2011) proposed two IL-15-based therapy strategies to target renal CSCs: (1) induction of paracrine IL-15 secretion by renal CSCs or neighboring cells mediated by gene transduction; (2) direct administration of IL-15 to the tumor tissue or delivery to the CSCs by coupling to peptides or antibodies which target to renal cancer cells or renal CSCs markers. </plain></SENT>
<SENT sid="48238" pm="."><plain>Due to the potential dual effect of IL-15 on both the differentiation of renal CSCs and the activation of an antitumor immune response, this therapy strategy could provide the foundations for the enhancement of renal carcinoma treatment. </plain></SENT>
<SENT sid="48239" pm="."><plain>A phase 1 study of the effect of intravenous human rhIL-15 in the treatment of mRCC has been completed recently (NCT01021059)2. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" position="float"><label>FIGURE 2</label><caption><p><text><SENT sid="48240" pm="."><plain>Interleukin (IL)-15-based targeting strategy for renal CSCs. CD105+ CSCs identified and isolated from human renal carcinomas were cultured with 10 pg/mL recombinant human IL-15, which induced the loss of stem cell markers and induced epithelial differentiation via the signaling pathway (IL-15Rαβγ chains). </plain></SENT>
<SENT sid="48241" pm="."><plain>The differentiated CD105+ CSCs lost their tumor-initiating and self-renewing abilities. </plain></SENT>
<SENT sid="48242" pm="."><plain>Endogenous IL-15-based autocrine loops were activated to induce permanent epithelial differentiation. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-07-00423-g002"/></fig></SecTag><p><text><SENT sid="48243" pm="."><plain>IL-21, a novel cytokine with structural and sequence homology to IL-2 and IL-15, has been studied extensively both in vitro and in vivo and evaluated in Phase 1 and 2 trials (NCT00617253, NCT00389285, and NCT00095108) in mRCC. </plain></SENT>
<SENT sid="48244" pm="."><plain>The data from these trials indicated that IL-21 has an acceptable safety profile and encouraging single agent activity in early phase RCC and melanoma clinical trials (Hashmi and Van Veldhuizen, 2010). </plain></SENT>
<SENT sid="48245" pm="."><plain>To date, it has not been shown if IL-21 has utility as a targeted therapy, similar to IL-15, in renal CSCs. </plain></SENT>
<SENT sid="48246" pm="."><plain>Further investigation is needed to determine the effect of IL-21 on renal cancer cells or CSCs in the treatment of RCC. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48247" pm="."><plain>CSC Surface Marker Inhibitors </plain></SENT>
</text></title><sec><title><text><SENT sid="48248" pm="."><plain>CD105/Endoglin Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="48249" pm="."><plain>Renal CSCs isolated from nephrectomy specimens express CD105/endoglin, allowing valuable therapeutic target for the tumor vasculature (Bussolati et al., 2008). </plain></SENT>
<SENT sid="48250" pm="."><plain>The identification of CD105/endoglin as a specific CSC marker was a solid buildup for treatment of RCC and its biology significance has been discussed as above. </plain></SENT>
<SENT sid="48251" pm="."><plain>CD105 expression is also upregulated by hypoxia through induction of HIF-1α or following inhibition of the VEGF pathway (Seon et al., 2011). </plain></SENT>
<SENT sid="48252" pm="."><plain>It is appealing to consider that the identification and inhibition of CSC markers may result in greater treatment efficacy in RCC. </plain></SENT>
<SENT sid="48253" pm="."><plain>The evaluation of anti-CD105/endoglin antibodies in RCC is a logical next step. </plain></SENT>
</text></p><p><text><SENT sid="48254" pm="."><plain>TRC105, a novel chimeric IgG1 anti-CD105/endoglin monoclonal antibody with high avidity, induces antibody-dependent cellular cytotoxicity and apoptosis in human umbilical vein endothelial cells and CD105+ tumor cells (Rosen et al., 2012). </plain></SENT>
<SENT sid="48255" pm="."><plain>Notably, the angiogenesis inhibition of TRC105 was much more impressive than the inhibition of human endothelial proliferation in vitro, emphasizing the importance of assays that mimic the interplay between endothelium and perivascular cells during angiogenesis (Rosen et al., 2014). </plain></SENT>
<SENT sid="48256" pm="."><plain>TRC105 is currently being evaluated for the treatment of RCC in Phase 1 and 2 trials (NCT01727089 and NCT01806064)2 (Choueiri et al., 2015a; Dorff et al., 2016). </plain></SENT>
<SENT sid="48257" pm="."><plain>Encouraging preliminary results showed that administration of 10 mg/kg TRC105 was well tolerated with axitinib in patients with RCC. </plain></SENT>
<SENT sid="48258" pm="."><plain>In addition, no TRC105-associated dose-limiting toxicities were observed with doses ranging from 8 to 10 mg/kg. </plain></SENT>
<SENT sid="48259" pm="."><plain>Most importantly, the combination of TRC105 and axitinib increased the overall response rate and doubled PFS compared with axitinib as a single agent (Choueiri et al., 2015b). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48260" pm="."><plain>CXCR4 Inhibitors </plain></SENT>
</text></title><p><text><SENT sid="48261" pm="."><plain>The CXCL12/CXCR4 biological axis, also discussed above, is another potential therapeutic target for RCC. </plain></SENT>
<SENT sid="48262" pm="."><plain>It is believed to play significant roles in tumorigenesis and metastasis (Gassenmaier et al., 2013). </plain></SENT>
<SENT sid="48263" pm="."><plain>Small-molecule antagonists and other strategies to downregulate CXCR4 expression have already been developed; these represent potential therapeutic strategies to inhibit tumors metastasis and enhance the survival of patients with RCC. </plain></SENT>
<SENT sid="48264" pm="."><plain>AMD3100 (commonly known as plerixafor, trade name Mozobil) is a specific CXCR4 antagonist that inhibits cancer cell tumorigenesis, disrupts the CSC niche, and sensitizes CSCs to chemotherapy (Yang and Wechsler-Reya, 2007). </plain></SENT>
<SENT sid="48265" pm="."><plain>Distinct from the commonly used method for the design of antagonists, three cyclic peptides were designed by Portella et al. (2013) as new CXCR4 antagonists. </plain></SENT>
<SENT sid="48266" pm="."><plain>These three CXCR4 inhibitory peptides were proven to be effective in inhibiting CXCR4-dependent migration and binding, P-ERK1/2-induction, calcium eﬄux, and tumor growth of renal cancer cells (Portella et al., 2013). </plain></SENT>
<SENT sid="48267" pm="."><plain>LY2510924 is a peptide antagonist of CXCR4 from Eli Lilly and Company and is currently in Phases 1 and 2 testing to evaluate its safety and efficacy in RCC (NCT01391130)3. </plain></SENT>
<SENT sid="48268" pm="."><plain>Preliminary data suggested that adding the CXCR4 inhibitor LY2510924 to sunitinib as a first-line treatment for metastatic RCC was tolerated but did not improve efficacy (Hainsworth et al., 2015, 2016). </plain></SENT>
</text></p><p><text><SENT sid="48269" pm="."><plain>RNA interference (RNAi), which has been proven to be a powerful tool for suppressing CXCR4 gene expression, has also been used as a treatment strategy in RCC. Wang et al. (2012b) developed recombinant CXCR4-RNAi plasmids that they transfected into RCC A-498 cells overexpressing CXCR4 in vitro. </plain></SENT>
<SENT sid="48270" pm="."><plain>Specific downregulation of CXCR4 by RNAi inhibited cell growth, invasion, and migration and induced cell apoptosis in RCC in vitro (Wang et al., 2012b). </plain></SENT>
</text></p><p><text><SENT sid="48271" pm="."><plain>Ierano et al. (2014) demonstrated that mTOR activation was specifically inhibited by CXCR4 antagonists in human renal cancer cells. </plain></SENT>
<SENT sid="48272" pm="."><plain>CXCR4 antagonists seem to regulate mTOR signaling in renal cancer cells, offering new therapeutic opportunities and targets to overcome resistance to mTOR inhibitors (Ierano et al., 2014). </plain></SENT>
<SENT sid="48273" pm="."><plain>Similarly, a newly discovered CXCL12 receptor, CXCR7, is highly expressed in RCC patients, indicating that CXCR7 may be useful a novel surface marker and therapeutic target for RCC (Maishi et al., 2012; Wang et al., 2012a). </plain></SENT>
</text></p></sec></sec><sec><title><text><SENT sid="48274" pm="."><plain>Bone Morphogenetic Protein-2 </plain></SENT>
</text></title><p><text><SENT sid="48275" pm="."><plain>Bone morphogenetic protein-2 is a member of the TGF superfamily. </plain></SENT>
<SENT sid="48276" pm="."><plain>It regulates various cellular processes including cell differentiation, proliferation, morphogenesis, cellular survival, and apoptosis, and has been shown to have an inhibitory effect in many tumor types (Ye et al., 2013; Zhang et al., 2014; Zheng et al., 2014). </plain></SENT>
<SENT sid="48277" pm="."><plain>However, the inhibitory effect of BMP-2 in tumors is controversial and some studies have shown that it stimulates tumor growth (Carragee et al., 2013; Liao et al., 2015), indicating that the action of BMP-2 on tumor growth probably depends on the cancer type. </plain></SENT>
<SENT sid="48278" pm="."><plain>Most recently, it has been reported that BMP-2 inhibits tumor growth in human RCC and induces bone formation (Wang et al., 2012c). </plain></SENT>
<SENT sid="48279" pm="."><plain>This study revealed that BMP-2 inhibited growth of the ACHN and Caki-2 cell lines, human RCC cell lines that express three types of BMP receptors. </plain></SENT>
<SENT sid="48280" pm="."><plain>This anti-proliferative effect seems to be due to cell cycle arrest in the G1 phase. </plain></SENT>
<SENT sid="48281" pm="."><plain>A follow-up study demonstrated that BMP-2 could inhibit the tumor-initiating ability of human renal ALDH+ CSCs, downregulate expression of embryonic stem cell markers, and upregulate transcription of osteogenic markers, suggesting that BMP-2 may therefore represent a beneficial treatment strategy for human RCC by targeting the CSC-enriched population (Wang et al., 2015). Mitsui et al. (2015) revealed that impaired regulation of BMP-2 via epigenetic pathways was associated with RCC pathogenesis, supporting a role for BMP-2 as a therapeutic strategy in RCC. </plain></SENT>
<SENT sid="48282" pm="."><plain>However, the poor absorption and instability of BMP-2 means that further research is needed to improve its drugability by pharmaceutical technologies; this could include PEGylation or packaging into liposomes or nanoparticles. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48283" pm="."><plain>Antibody Drug Conjugates (ADCs) </plain></SENT>
</text></title><p><text><SENT sid="48284" pm="."><plain>An ADC is comprised of a monoclonal antibody conjugated to a cytotoxin that specifically binds to cell-surface antigens on the target cell; it represents a novel method for the treatment of mRCC (Goldmacher and Kovtun, 2011). </plain></SENT>
<SENT sid="48285" pm="."><plain>Such conjugates have received significant attention since positive results in breast cancer were reported for TDM-1 (Kadcyla; Roche), a conjugate of the monoclonal antibody trastuzumab and the cytotoxin maytansine (Verma et al., 2012; Dhillon, 2014). </plain></SENT>
<SENT sid="48286" pm="."><plain>SGN-75, a humanized anti-CD70 monoclonal antibody conjugated to monomethyl auristatin F (MMAF) through a maleimidocaproyl (mc) linker (mcMMAF), has been evaluated in a phase 1 clinical trial for mRCC and for relapsed or refractory non-Hodgkin lymphoma (NCT01015911)4. </plain></SENT>
<SENT sid="48287" pm="."><plain>Encouraging antitumor activity has been observed in both mRCC patients and in relapsed/refractory non-Hodgkin lymphoma patients. </plain></SENT>
</text></p><p><text><SENT sid="48288" pm="."><plain>Wilms’ tumor (WT), a common pediatric solid renal tumor, is formed when renal precursor cells fail to differentiate properly. Pode-Shakked et al. (2013) successfully isolated and characterized WT CSCs expressing NCAM from human WT xenografts, and showed that lorvotuzumab mertansine (mertansine, also known as DM1, is a derivative of maytansine), an anti-NCAM antibody/cytotoxic drug conjugate, can dramatically reduce the expression of NCAM in WT cells from 42 to 5%, in addition to inducing a significant reduction in the colony forming capacity of treated cells (Pode-Shakked et al., 2013). </plain></SENT>
<SENT sid="48289" pm="."><plain>A follow-up study showed that targeting the human NCAM+ cell fraction with lorvotuzumab-mertansine resulted in the loss of WT CSCs and induced a reduction in tumor size in the majority of cases, both in vitro and in vivo, followed by complete tumor degradation (Figure 3) (Pode-Shakked et al., 2013; Shukrun et al., 2014). </plain></SENT>
<SENT sid="48290" pm="."><plain>A phase 2 trial evaluating lorvotuzumab-mertansine is ongoing (NCT02452554). </plain></SENT>
<SENT sid="48291" pm="."><plain>Therefore, it can be concluded that using ADCs to deplete the stemness properties of CSCs by targeting ligands on the CSC cell surface may improve the impact of conventional chemotherapy. </plain></SENT>
<SENT sid="48292" pm="."><plain>This would consequently result in a clinically relevant benefit for patients. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F3" position="float"><label>FIGURE 3</label><caption><p><text><SENT sid="48293" pm="."><plain>A strategy to target human NCAM+ cells with lorvotuzumab mertansine. Targeted therapy resulted in loss of Wilms’ tumor CSCs and a reduction in tumor size in the majority of cases, both in vitro and in vivo, followed by complete tumor degradation. </plain></SENT>
</text></p></caption><graphic xlink:href="fphar-07-00423-g003"/></fig></SecTag></sec><sec><title><text><SENT sid="48294" pm="."><plain>Nanomedical Strategies </plain></SENT>
</text></title><p><text><SENT sid="48295" pm="."><plain>Recently, molecularly directed nanomedicine has become an appealing option as an RCC targeted therapy. </plain></SENT>
<SENT sid="48296" pm="."><plain>Nanomedical strategies can control drug delivery and release more efficiently than other methods. </plain></SENT>
<SENT sid="48297" pm="."><plain>Nanoparticles are high-capacity carriers for active compounds. </plain></SENT>
<SENT sid="48298" pm="."><plain>They can easily accumulate at tumor sites due to the high porosity of the tumor vasculature, impaired lymphatic drainage (known as the enhanced permeability and retention effect), or the high affinity of the nanoparticle to markers specifically expressed on cancer cells. </plain></SENT>
<SENT sid="48299" pm="."><plain>The typical nanomedicine delivery vehicles include liposomes, polymeric nanoparticles, nucleic acid based nanoparticles, dendrimers, magnetic nanoparticles, nanoshells, and virus nanoparticles. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48300" pm="."><plain>Liposomes </plain></SENT>
</text></title><p><text><SENT sid="48301" pm="."><plain>Liu et al. (2015a,b) systemically evaluated the in vitro performance of sorafenib-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles, 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) liposomes, and hydrophobically modified chitosan (HMC)-coated DPPC as delivery systems in the treatment of RCC. </plain></SENT>
<SENT sid="48302" pm="."><plain>The results of this study showed that sorafenib-loaded PLGA nanoparticles and HMC-coated DPPC liposomes could kill significantly more tumor cells than sorafenib alone at lower concentrations; these methods could be further developed as unique clinical modalities and paired with ablative particles for synergistic treatments (Liu et al., 2015a,b). </plain></SENT>
<SENT sid="48303" pm="."><plain>Recently, Kulkarni et al. (2016) showed that liposomes encapsulating a multi-receptor tyrosine kinase inhibitor (XL184) significantly increased anti-tumor activity than XL184 alone. </plain></SENT>
<SENT sid="48304" pm="."><plain>They also found that the mechanism of XL184 liposomes’ anti-tumor activity is through inhibition of phosphorylation of Met, AKT, and MAPK pathways in RCC cells (Kulkarni et al., 2016). </plain></SENT>
<SENT sid="48305" pm="."><plain>These results indicated that use of liposomes for multi-kinase pathways inhibition may emerge as a promising treatment option for RCC. </plain></SENT>
</text></p><p><text><SENT sid="48306" pm="."><plain>In another study, Kibria et al. (2016) addressed the discrepancy of antitumor effect of PEGylated liposomal Doxorubicin (PEG-LP (DOX)) in two tumor models. </plain></SENT>
<SENT sid="48307" pm="."><plain>PEG-LP (DOX) failed to suppress the growth of the RCC OSRC-2 xenograft tumors. </plain></SENT>
<SENT sid="48308" pm="."><plain>However, it could suppress breast cancer MDA-MB-231 xenograft tumor growth. </plain></SENT>
<SENT sid="48309" pm="."><plain>Furthermore, they showed that extracellular matrix (ECM) molecules of MDA-MB-231 tumor limited the extent of the penetration and distribution of PEG-LP, which in turn enhancing the delivery of DOX to tumor vasculature. </plain></SENT>
<SENT sid="48310" pm="."><plain>Therefore, these findings highlight the unique characteristics of tumor microenvironment that could be exploited by nanomedicine for developing novel drug delivery systems (Kibria et al., 2016). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="48311" pm="."><plain>Polymeric Nanoparticles </plain></SENT>
</text></title><p><text><SENT sid="48312" pm="."><plain>Sumitomo et al. (2008) have used polymeric micelles incorporated with 7-Ethyl-10-hydroxy-camptothecin (SN38) to treat the RCC xenograft murine model. </plain></SENT>
<SENT sid="48313" pm="."><plain>This nanoparticle significantly reduced the bulk of tumors and decreased the metastatic nodule number than free drug alone (Sumitomo et al., 2008). </plain></SENT>
<SENT sid="48314" pm="."><plain>New studies showed that CRLX101, a nanoparticle-drug conjugate containing camptothecin conjugated to a biocompatible cyclodextrin/polyethylene glycol (PEG) copolymer, is currently being evaluated pre-clinically and clinically in multiple tumor types (Gaur et al., 2014; Lin et al., 2016). </plain></SENT>
<SENT sid="48315" pm="."><plain>A phase I trial of CRLX101 in combination with bevacizumab for mRCC therapy has recently been completed (NCT016259365). </plain></SENT>
<SENT sid="48316" pm="."><plain>The preliminary data showed that CRLX101 combined with bevacizumab is a safe treatment in mRCC. </plain></SENT>
<SENT sid="48317" pm="."><plain>This combination fulfilled the protocol’s predefined threshold for further examination with responses and prolonged PFS in a heavily pretreated population (Keefe et al., 2016). </plain></SENT>
<SENT sid="48318" pm="."><plain>A randomized phase II clinical trial in mRCC of this combination is ongoing (NCT02187302). </plain></SENT>
</text></p><p><text><SENT sid="48319" pm="."><plain>Several studies have proposed to target RCC using nanocarriers, but, to date, these approaches have not been investigated in renal CSCs. </plain></SENT>
<SENT sid="48320" pm="."><plain>Nanoparticles effectively inhibit multiple types of CSCs by targeting specific markers, including ALDH, CD44, and CD133, and/or specific signaling pathways and other key developmental signaling pathways implicated in the maintenance of the CSC pool of many tumors (Lu et al., 2016). </plain></SENT>
<SENT sid="48321" pm="."><plain>Nanomedical strategies for renal CSCs are under research and development and a comprehensive evaluation of the approaches should be available soon. </plain></SENT>
</text></p><p><text><SENT sid="48322" pm="."><plain>As mentioned above, renal tumors from patients show strong resistance to conventional anti-cancer drugs such as interferon α and interleukins. </plain></SENT>
<SENT sid="48323" pm="."><plain>TKIs have significantly improved outcome in patients with metastatic disease, while drug resistance still prevails in most patients over time because of the intricate tumor evasion mechanisms. </plain></SENT>
<SENT sid="48324" pm="."><plain>TRC105 and CXCR4 inhibitors seem to be the promising drugs for renal tumors underlining the importance of specific surface markers (CD105 and CXCR4) of renal CSCs. </plain></SENT>
<SENT sid="48325" pm="."><plain>According to the newly discovery of specific expression pattern in renal CSCs, some specific markers are further developed for obtaining the benefits of less resistance and enhanced therapy. </plain></SENT>
<SENT sid="48326" pm="."><plain>And great interests are emerging to develop new therapeutic drugs or immunotoxins targeting renal CSCs based on molecular mechanisms that regulate stem cell properties. </plain></SENT>
<SENT sid="48327" pm="."><plain>Despite progress being made in developing targeted strategies for renal cancer and renal CSCs, more approaches are still need to be explored notwithstanding the numerous impediments. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec><title><text><SENT sid="48328" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="48329" pm="."><plain>Increasing evidence has shown that CSCs play a key role in cancer drug resistance, radiation therapy resistance, and are responsible for disease recurrence. </plain></SENT>
<SENT sid="48330" pm="."><plain>With the development of the CSC hypothesis, new concepts and approaches for eradicating malignancies have emerged. </plain></SENT>
<SENT sid="48331" pm="."><plain>It has been shown that renal carcinomas possess CSCs with mesenchymal properties, and self-renewal and multi-differentiation properties, although a definitive selection marker for their isolation and targeting remains to be found. </plain></SENT>
<SENT sid="48332" pm="."><plain>Subpopulations of renal CSCs may coexist within a heterogeneous tumor, which means that renal CSC targeting therapy is a complicated science. </plain></SENT>
<SENT sid="48333" pm="."><plain>A vast body of targeted therapies has been developed, and the systemic treatment of RCC has advanced in recent years. </plain></SENT>
<SENT sid="48334" pm="."><plain>These advances have focused on inhibition of the VEGF and mTOR pathways, markers (such as CD105 and CXCR4), and differentiation of renal CSCs. </plain></SENT>
<SENT sid="48335" pm="."><plain>During the last few years, numerous new clinical trials have been undertaken, or are currently recruiting. </plain></SENT>
<SENT sid="48336" pm="."><plain>Even if obvious limitations exist in reaching renal CSCs in vivo owing to the inaccessibility of the entire tumor area or because of the tumor microenvironment, these limitations may be overcome with the use of ADCs and nanomedical strategies. </plain></SENT>
<SENT sid="48337" pm="."><plain>Multimodal CSC-targeting strategies combined with new pathway specific modulators and cytotoxic agents may also contribute to overcoming the limitations in RCC treatment. </plain></SENT>
<SENT sid="48338" pm="."><plain>Successful therapeutic exploitation of renal CSCs will help us to better understand the role of CSCs in different treatment responses, different stages of disease, and different patients. </plain></SENT>
<SENT sid="48339" pm="."><plain>Precise identification of renal CSCs populations and the complete cell hierarchy will enable the accurate characterization of disease subtypes. </plain></SENT>
<SENT sid="48340" pm="."><plain>This will ultimately lead to more personalized and targeted therapies. </plain></SENT>
<SENT sid="48341" pm="."><plain>Rationally designed targeting therapy for RCC unseals new directions for exploration and clinical investigation and plants the seeds of hope for advanced clinical care. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec><title><text><SENT sid="48342" pm="."><plain>Author Contributions </plain></SENT>
</text></title><p><text><SENT sid="48343" pm="."><plain>Z-XY summarized the literature and wrote the manuscript. </plain></SENT>
<SENT sid="48344" pm="."><plain>JM provided critical comments and wrote the manuscript. </plain></SENT>
<SENT sid="48345" pm="."><plain>GZ and GS revised the manuscript and drew figures. </plain></SENT>
<SENT sid="48346" pm="."><plain>H-LF and WZ supervised all the works and provided critical comments. </plain></SENT>
</text></p></sec></SecTag><SecTag type="COMP_INT"><sec><title><text><SENT sid="48347" pm="."><plain>Conflict of Interest Statement </plain></SENT>
</text></title><p><text><SENT sid="48348" pm="."><plain>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></sec></SecTag></body><back><fn-group><SecTag type="ACK_FUND"><fn fn-type="financial-disclosure"><p><text4fund><text><SENT sid="48349" pm="."><plain>Funding. This work was supported by National Science Foundation of China (No. 81202489 and 81572766) and SYSU Young Teachers Training Program (No. 16YKZD14). </plain></SENT>
</text></text4fund></p></fn></SecTag></fn-group><SecTag type="ACK_FUND"><ack><p><text4fund><text><SENT sid="48350" pm="."><plain>We thank Ms. </plain></SENT>
<SENT sid="48351" pm="."><plain>Xiaohui Ma for valuable suggestions. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn id="fn01"><label>1</label><p><text><SENT sid="48352" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> </plain></SENT>
</text></p></fn><fn id="fn02"><label>2</label><p><text><SENT sid="48353" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> </plain></SENT>
</text></p></fn><fn id="fn03"><label>3</label><p><text><SENT sid="48354" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> </plain></SENT>
</text></p></fn><fn id="fn04"><label>4</label><p><text><SENT sid="48355" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> </plain></SENT>
</text></p></fn><fn id="fn05"><label>5</label><p><text><SENT sid="48356" pm="."><plain><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="48357" pm="."><plain>AddlaS. </plain></SENT>
<SENT sid="48358" pm="."><plain>K.BrownM. </plain></SENT>
<SENT sid="48359" pm="."><plain>D.HartC. </plain></SENT>
<SENT sid="48360" pm="."><plain>A.RamaniV. </plain></SENT>
<SENT sid="48361" pm="."><plain>A.ClarkeN. </plain></SENT>
<SENT sid="48362" pm="."><plain>W. (2008). Characterization of the Hoechst 33342 side population from normal and malignant human renal epithelial cells. Am. </plain></SENT>
<SENT sid="48363" pm="."><plain>J. </plain></SENT>
<SENT sid="48364" pm="."><plain>Physiol. </plain></SENT>
<SENT sid="48365" pm="."><plain>Renal Physiol. 295 F680–F687. 10.1152/ajprenal.90286.200818614618 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="48366" pm="."><plain>AlbigesL.OudardS.NegrierS.CatyA.GravisG.JolyF. (2012). Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J. Clin. </plain></SENT>
<SENT sid="48368" pm="."><plain>Oncol. 30 482–487. 10.1200/JCO.2011.37.251622231040 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="48369" pm="."><plain>AmatoR. </plain></SENT>
<SENT sid="48370" pm="."><plain>J.FlahertyA. </plain></SENT>
<SENT sid="48371" pm="."><plain>L.StepankiwM. (2012). Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer. Clin. </plain></SENT>
<SENT sid="48372" pm="."><plain>Genitourin. </plain></SENT>
<SENT sid="48373" pm="."><plain>Cancer 10 26–31. 10.1016/j.clgc.2011.11.00222169794 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="48374" pm="."><plain>AsatiV.MahapatraD. </plain></SENT>
<SENT sid="48375" pm="."><plain>K.BhartiS. </plain></SENT>
<SENT sid="48376" pm="."><plain>K. (2016). PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives. Eur. </plain></SENT>
<SENT sid="48377" pm="."><plain>J. </plain></SENT>
<SENT sid="48378" pm="."><plain>Med. </plain></SENT>
<SENT sid="48379" pm="."><plain>Chem. 109 314–341. 10.1016/j.ejmech.2016.01.01226807863 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="48380" pm="."><plain>AulitzkyW. </plain></SENT>
<SENT sid="48381" pm="."><plain>E.SchulerM.PeschelC.HuberC. (1994). Interleukins. </plain></SENT>
<SENT sid="48382" pm="."><plain>Clinical pharmacology and therapeutic use. Drugs 48 667–677. 10.2165/00003495-199448050-000027530625 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="48383" pm="."><plain>AzziS.BrunoS.Giron-MichelJ.ClayD.DevocelleA.CroceM. (2011). Differentiation therapy: targeting human renal cancer stem cells with interleukin 15. J. Natl. </plain></SENT>
<SENT sid="48385" pm="."><plain>Cancer Inst. 103 1884–1898. 10.1093/jnci/djr45122043039 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="48386" pm="."><plain>BieleckaZ. </plain></SENT>
<SENT sid="48387" pm="."><plain>F.CzarneckaA. </plain></SENT>
<SENT sid="48388" pm="."><plain>M.SzczylikC. (2014). Genomic analysis as the first step toward personalized treatment in renal cell carcinoma. Front. </plain></SENT>
<SENT sid="48389" pm="."><plain>Oncol. 4:194 10.3389/fonc.2014.00194 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="48390" pm="."><plain>BrunoS.BussolatiB.GrangeC.CollinoF.GrazianoM. </plain></SENT>
<SENT sid="48391" pm="."><plain>E.FerrandoU. (2006). CD133+ renal progenitor cells contribute to tumor angiogenesis. Am. </plain></SENT>
<SENT sid="48392" pm="."><plain>J. </plain></SENT>
<SENT sid="48393" pm="."><plain>Pathol. 169 2223–2235. 10.2353/ajpath.2006.06049817148683 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="48394" pm="."><plain>BussolatiB.BrossaA.CamussiG. (2011). Resident stem cells and renal carcinoma. Int. </plain></SENT>
<SENT sid="48395" pm="."><plain>J. </plain></SENT>
<SENT sid="48396" pm="."><plain>Nephrol. 2011:286985 10.4061/2011/286985 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="48397" pm="."><plain>BussolatiB.BrunoS.GrangeC.ButtiglieriS.DeregibusM. </plain></SENT>
<SENT sid="48398" pm="."><plain>C.CantinoD. (2005). Isolation of renal progenitor cells from adult human kidney. Am. </plain></SENT>
<SENT sid="48399" pm="."><plain>J. </plain></SENT>
<SENT sid="48400" pm="."><plain>Pathol. 166 545–555. 10.1016/S0002-9440(10)62276-615681837 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="48401" pm="."><plain>BussolatiB.BrunoS.GrangeC.FerrandoU.CamussiG. (2008). Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J. 22 3696–3705. 10.1096/fj.08-10259018614581 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="48402" pm="."><plain>BussolatiB.DekelB.AzzaroneB.CamussiG. (2013). Human renal cancer stem cells. Cancer Lett. 338 141–146. 10.1016/j.canlet.2012.05.00722587951 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="48403" pm="."><plain>CarrageeE. </plain></SENT>
<SENT sid="48404" pm="."><plain>J.ChuG.RohatgiR.HurwitzE. </plain></SENT>
<SENT sid="48405" pm="."><plain>L.WeinerB. </plain></SENT>
<SENT sid="48406" pm="."><plain>K.YoonS. </plain></SENT>
<SENT sid="48407" pm="."><plain>T. (2013). Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis. J. Bone Joint Surg. </plain></SENT>
<SENT sid="48409" pm="."><plain>Am. 95 1537–1545. 10.2106/JBJS.L.0148324005193 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="48410" pm="."><plain>ChoueiriT. </plain></SENT>
<SENT sid="48411" pm="."><plain>K.AgarwalN.HoT. </plain></SENT>
<SENT sid="48412" pm="."><plain>H.PachynskiR.PalS.RyanC. </plain></SENT>
<SENT sid="48413" pm="."><plain>W. (2015a). TRAXAR Study: A Randomized Phase 2 Trial of Axitinib and TRC105 Versus AXitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (mRCC). Hoboken, NJ: Wiley-Blackwell 5–6. </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="48414" pm="."><plain>ChoueiriT. </plain></SENT>
<SENT sid="48415" pm="."><plain>K.MichaelsonM. </plain></SENT>
<SENT sid="48416" pm="."><plain>D.PosadasE. </plain></SENT>
<SENT sid="48417" pm="."><plain>M.SonpavdeG.McdermottD. </plain></SENT>
<SENT sid="48418" pm="."><plain>F. (2015b). “A phase 1b dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC),” in Proceedings of the 14th International Kidney Cancer Symposium Miami, FL. </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="48419" pm="."><plain>CleversH. (2011). The cancer stem cell: premises, promises and challenges. Nat. </plain></SENT>
<SENT sid="48420" pm="."><plain>Med. 17 313–319. 10.1038/nm.230421386835 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="48421" pm="."><plain>CohenR. </plain></SENT>
<SENT sid="48422" pm="."><plain>B.OudardS. (2012). Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest. </plain></SENT>
<SENT sid="48423" pm="."><plain>New Drugs 30 2066–2079. 10.1007/s10637-012-9796-822327313 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="48424" pm="."><plain>ConcepcionC. </plain></SENT>
<SENT sid="48425" pm="."><plain>P.BonettiC.VenturaA. (2012). The microRNA-17-92 family of microRNA clusters in development and disease. Cancer J. 18 262–267. 10.1097/PPO.0b013e318258b60a22647363 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="48426" pm="."><plain>CostaW. </plain></SENT>
<SENT sid="48427" pm="."><plain>H.RochaR. </plain></SENT>
<SENT sid="48428" pm="."><plain>M.CunhaI. </plain></SENT>
<SENT sid="48429" pm="."><plain>W.FonsecaF. </plain></SENT>
<SENT sid="48430" pm="."><plain>P.GuimaraesG. </plain></SENT>
<SENT sid="48431" pm="."><plain>C.Zequi SdeC. (2012). CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma. World J. Urol. 30 553–558. 10.1007/s00345-011-0769-x21969131 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="48433" pm="."><plain>CreaF.DuhagonM. </plain></SENT>
<SENT sid="48434" pm="."><plain>A.FarrarW. </plain></SENT>
<SENT sid="48435" pm="."><plain>L.DanesiR. (2011). Pharmacogenomics and cancer stem cells: a changing landscape? Trends Pharmacol. </plain></SENT>
<SENT sid="48436" pm="."><plain>Sci. 32 487–494. 10.1016/j.tips.2011.03.01021529973 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="48437" pm="."><plain>CzarneckaA. </plain></SENT>
<SENT sid="48438" pm="."><plain>M.KornakiewiczA.LianF.SzczylikC. (2015a). Future perspectives for mTOR inhibitors in renal cell cancer treatment. Future Oncol. 11 801–817. 10.2217/fon.14.30325757683 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="48439" pm="."><plain>CzarneckaA. </plain></SENT>
<SENT sid="48440" pm="."><plain>M.OborskaS.RzepeckiP.SzczylikC. (2015b). Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. Future Oncol. 11 17–26. 10.2217/fon.14.135 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="48441" pm="."><plain>CzarneckaA. </plain></SENT>
<SENT sid="48442" pm="."><plain>M.SolarekW.KornakiewiczA.SzczylikC. (2016). Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer. Oncol. </plain></SENT>
<SENT sid="48443" pm="."><plain>Rep. 35 1433–1442. 10.3892/or.2015.451426708631 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="48444" pm="."><plain>D’ AlterioC.PortellaL.OttaianoA.RizzoM.CarteniG.PignataS. (2012). High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer. Curr. </plain></SENT>
<SENT sid="48445" pm="."><plain>Cancer Drug Targets 12 693–702. 10.2174/15680091280178482022463589 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="48446" pm="."><plain>DallasN. </plain></SENT>
<SENT sid="48447" pm="."><plain>A.SamuelS.XiaL.FanF.GrayM. </plain></SENT>
<SENT sid="48448" pm="."><plain>J.LimS. </plain></SENT>
<SENT sid="48449" pm="."><plain>J. (2008). Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin. </plain></SENT>
<SENT sid="48450" pm="."><plain>Cancer Res. 14 1931–1937. 10.1158/1078-0432.CCR-07-447818381930 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="48451" pm="."><plain>DebebB. </plain></SENT>
<SENT sid="48452" pm="."><plain>G.ZhangX.KrishnamurthyS.GaoH.CohenE.LiL. (2010). Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol. </plain></SENT>
<SENT sid="48453" pm="."><plain>Cancer 9:180 10.1186/1476-4598-9-180 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="48454" pm="."><plain>DhillonS. (2014). Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. Drugs 74 675–686. 10.1007/s40265-014-0201-024659374 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="48455" pm="."><plain>Di LorenzoG.BuonerbaC.BigliettoM.ScognamiglioF.ChiurazziB.RiccardiF. (2010). The therapy of kidney cancer with biomolecular drugs. Cancer Treat. </plain></SENT>
<SENT sid="48456" pm="."><plain>Rev. 36(Suppl. </plain></SENT>
<SENT sid="48457" pm="."><plain>3) S16–S20. 10.1016/S0305-7372(10)70015-321129605 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="48458" pm="."><plain>DorffT. </plain></SENT>
<SENT sid="48459" pm="."><plain>B.LongmateJ.GroshenS. </plain></SENT>
<SENT sid="48460" pm="."><plain>G.StadlerW. </plain></SENT>
<SENT sid="48461" pm="."><plain>M.FishmanM. </plain></SENT>
<SENT sid="48462" pm="."><plain>N.VaishampayanU. </plain></SENT>
<SENT sid="48463" pm="."><plain>N. (2016). “Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC),” in Proceedings of the ASCO Annual Meeting Chicago, IL 522. </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="48464" pm="."><plain>DranoffG. (2004). Cytokines in cancer pathogenesis and cancer therapy. Nat. </plain></SENT>
<SENT sid="48465" pm="."><plain>Rev. </plain></SENT>
<SENT sid="48466" pm="."><plain>Cancer 4 11–22. 10.1038/nrc125214708024 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="48467" pm="."><plain>EichelbergC.HeuerR.ChunF. </plain></SENT>
<SENT sid="48468" pm="."><plain>K.HinrichsK.ZachariasM.HulandH. (2008). Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur. </plain></SENT>
<SENT sid="48469" pm="."><plain>Urol. 54 1373–1378. 10.1016/j.eururo.2008.07.05118692304 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="48470" pm="."><plain>FrancipaneM. </plain></SENT>
<SENT sid="48471" pm="."><plain>G.LagasseE. (2013). Selective targeting of human colon cancer stem-like cells by the mTOR inhibitor Torin-1. Oncotarget 4 1948–1962. 10.18632/oncotarget.131024185040 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="48472" pm="."><plain>FriedL. </plain></SENT>
<SENT sid="48473" pm="."><plain>E.ArbiserJ. </plain></SENT>
<SENT sid="48474" pm="."><plain>L. (2009). Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid. </plain></SENT>
<SENT sid="48475" pm="."><plain>Redox Signal. 11 1139–1148. 10.1089/ARS.2009.244019203212 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="48476" pm="."><plain>FriedmanM. </plain></SENT>
<SENT sid="48477" pm="."><plain>D.JeevanD. </plain></SENT>
<SENT sid="48478" pm="."><plain>S.TobiasM.MuraliR.Jhanwar-UniyalM. (2013). Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Oncol. </plain></SENT>
<SENT sid="48479" pm="."><plain>Rep. 30 1645–1650. 10.3892/or.2013.262523877261 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="48480" pm="."><plain>GassenmaierM.ChenD.BuchnerA.HenkelL.SchiemannM.MackB. (2013). CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis. Stem Cells 31 1467–1476. 10.1002/stem.140723630186 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="48481" pm="."><plain>GaurS.WangY.KretznerL.ChenL.YenT.WuX. (2014). Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer. Nanomedicine 10 1477–1486. 10.1016/j.nano.2014.04.00324768630 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="48482" pm="."><plain>GedalyR.GaluppoR.MusgraveY.AnguloP.HundleyJ.ShahM. (2013). PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J. Surg. </plain></SENT>
<SENT sid="48484" pm="."><plain>Res. 185 225–230. 10.1016/j.jss.2013.05.01623769634 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="48485" pm="."><plain>GerlingerM.RowanA. </plain></SENT>
<SENT sid="48486" pm="."><plain>J.HorswellS.LarkinJ.EndesfelderD.GronroosE. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. </plain></SENT>
<SENT sid="48488" pm="."><plain>J. </plain></SENT>
<SENT sid="48489" pm="."><plain>Med. 366 883–892. 10.1056/NEJMoa111320522397650 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="48490" pm="."><plain>Giron-MichelJ.AzziS.FerriniS.ChouaibS.CamussiG.EidP. (2013). Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev. 24 13–22. 10.1016/j.cytogfr.2012.08.00622981349 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="48491" pm="."><plain>Giron-MichelJ.AzziS.KhawamK.MortierE.CaignardA.DevocelleA. (2012). Interleukin-15 plays a central role in human kidney physiology and cancer through the gammac signaling pathway. PLoS ONE 7:e31624 10.1371/journal.pone.0031624 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="48492" pm="."><plain>GoldmacherV. </plain></SENT>
<SENT sid="48493" pm="."><plain>S.KovtunY. </plain></SENT>
<SENT sid="48494" pm="."><plain>V. (2011). Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells. Ther. </plain></SENT>
<SENT sid="48495" pm="."><plain>Deliv. 2 397–416. 10.4155/tde.10.9822834009 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="48496" pm="."><plain>Grosse-GehlingP.FargeasC. </plain></SENT>
<SENT sid="48497" pm="."><plain>A.DittfeldC.GarbeY.AlisonM. </plain></SENT>
<SENT sid="48498" pm="."><plain>R.CorbeilD. (2013). CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J. Pathol. 229 355–378. 10.1002/path.408622899341 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="48500" pm="."><plain>GuptaS.RosenbergM. </plain></SENT>
<SENT sid="48501" pm="."><plain>E. (2008). Do stem cells exist in the adult kidney? Am. </plain></SENT>
<SENT sid="48502" pm="."><plain>J. </plain></SENT>
<SENT sid="48503" pm="."><plain>Nephrol. 28 607–613. 10.1159/00011731118285682 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="48504" pm="."><plain>GuptaS.VerfaillieC.ChmielewskiD.KrenS.EidmanK.ConnaireJ. (2006). Isolation and characterization of kidney-derived stem cells. J. Am. </plain></SENT>
<SENT sid="48506" pm="."><plain>Soc. </plain></SENT>
<SENT sid="48507" pm="."><plain>Nephrol. 17 3028–3040. 10.1681/ASN.200603027516988061 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="48508" pm="."><plain>HainsworthJ. </plain></SENT>
<SENT sid="48509" pm="."><plain>D.MaceJ. </plain></SENT>
<SENT sid="48510" pm="."><plain>R.ReevesJ. </plain></SENT>
<SENT sid="48511" pm="."><plain>A.CraneE. </plain></SENT>
<SENT sid="48512" pm="."><plain>J.HamidO.StilleJ. </plain></SENT>
<SENT sid="48513" pm="."><plain>R. (2015). “Randomized phase II study of sunitinib+ CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma,” in Proceedings of the ASCO Annual Meeting Chicago, IL 4547. </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="48514" pm="."><plain>HainsworthJ. </plain></SENT>
<SENT sid="48515" pm="."><plain>D.ReevesJ. </plain></SENT>
<SENT sid="48516" pm="."><plain>A.MaceJ. </plain></SENT>
<SENT sid="48517" pm="."><plain>R.CraneE. </plain></SENT>
<SENT sid="48518" pm="."><plain>J.HamidO.StilleJ. </plain></SENT>
<SENT sid="48519" pm="."><plain>R. (2016). A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC). Target. </plain></SENT>
<SENT sid="48520" pm="."><plain>Oncol. 11 643–653. 10.1007/s11523-016-0434-927154357 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="48521" pm="."><plain>HashmiM. </plain></SENT>
<SENT sid="48522" pm="."><plain>H.Van VeldhuizenP. </plain></SENT>
<SENT sid="48523" pm="."><plain>J. (2010). Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin’s lymphoma. Expert Opin. </plain></SENT>
<SENT sid="48524" pm="."><plain>Biol. </plain></SENT>
<SENT sid="48525" pm="."><plain>Ther. 10 807–817. 10.1517/14712598.2010.48097120384523 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="48526" pm="."><plain>HiragaT.ItoS.NakamuraH. (2013). Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. Cancer Res. 73 4112–4122. 10.1158/0008-5472.CAN-12-380123633482 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="48527" pm="."><plain>HumphreysB. </plain></SENT>
<SENT sid="48528" pm="."><plain>D.ValeriusM. </plain></SENT>
<SENT sid="48529" pm="."><plain>T.KobayashiA.MugfordJ. </plain></SENT>
<SENT sid="48530" pm="."><plain>W.SoeungS.DuffieldJ. </plain></SENT>
<SENT sid="48531" pm="."><plain>S. (2008). Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2 284–291. 10.1016/j.stem.2008.01.01418371453 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="48532" pm="."><plain>IeranoC.SantagataS.NapolitanoM.GuardiaF.GrimaldiA.AntignaniE. (2014). CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis. 5:e1310 10.1038/cddis.2014.269 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="48533" pm="."><plain>JangS.ZhengC.TsaiH. </plain></SENT>
<SENT sid="48534" pm="."><plain>T.FuA. </plain></SENT>
<SENT sid="48535" pm="."><plain>Z.BaracA.AtkinsM. </plain></SENT>
<SENT sid="48536" pm="."><plain>B. (2016). Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma. Cancer 122 124–130. 10.1002/cncr.2972826439451 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="48537" pm="."><plain>JobardE.BlancE.NegrierS.EscudierB.GravisG.ChevreauC. (2015). A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. Br. </plain></SENT>
<SENT sid="48538" pm="."><plain>J. </plain></SENT>
<SENT sid="48539" pm="."><plain>Cancer 113 1148–1157. 10.1038/bjc.2015.32226372698 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="48540" pm="."><plain>KavacsG.AkhtarM.BeckwithB. (1997). The Heidelberg classification of renal cell tumors. J. Pathol. 183 131–133. 10.1002/(SICI)1096-9896(199710)183:2&lt;131::AID-PATH931&gt;3.0.CO;2-G9390023 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="48542" pm="."><plain>KeefeS.Hoffman-CensitsJ.CohenR.MamtaniR.HeitjanD.EliasofS. (2016). Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trial. Ann. </plain></SENT>
<SENT sid="48543" pm="."><plain>Oncol. 27 1579–1585. 10.1093/annonc/mdw18827457310 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="48544" pm="."><plain>KhanM.CzarneckaA.KrolM.ZdanowskiR.SobocinskaA.LewickiS. (2013). “Analysis of tumor initiating cells (TICs) populations in primary and metastatic cell lines from clear cell renal cell carcinoma (ccRCC),” in Proceedings of the 4th International Conference on Stem Cells and Cancer (ICSCC-2013) Mumbai 73–74. </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="48545" pm="."><plain>KhanM.CzarneckaA.SzczylikC. (2012). “Detection of CD105+ and CD133+ sub-populations (cancer initiating cells) in SMKT-R2, SMKT-R3 and 786-(O)human primary renal cancer cell lines,” in Proceedings of the 4th EMBO Meeting Mannheim 212–213. </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="48546" pm="."><plain>KibriaG.HatakeyamaH.SatoY.HarashimaH. (2016). Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors. Int. </plain></SENT>
<SENT sid="48547" pm="."><plain>J. </plain></SENT>
<SENT sid="48548" pm="."><plain>Pharm. 509 178–187. 10.1016/j.ijpharm.2016.05.04727234700 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="48549" pm="."><plain>KimK.IhmH.RoJ. </plain></SENT>
<SENT sid="48550" pm="."><plain>Y.ChoY. </plain></SENT>
<SENT sid="48551" pm="."><plain>M. (2011). High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis. Oncol. </plain></SENT>
<SENT sid="48552" pm="."><plain>Lett. 2 1095–1100.22848273 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="48553" pm="."><plain>KolevV. </plain></SENT>
<SENT sid="48554" pm="."><plain>N.WrightQ. </plain></SENT>
<SENT sid="48555" pm="."><plain>G.VidalC. </plain></SENT>
<SENT sid="48556" pm="."><plain>M.RingJ. </plain></SENT>
<SENT sid="48557" pm="."><plain>E.ShapiroI. </plain></SENT>
<SENT sid="48558" pm="."><plain>M.RiconoJ. (2015). PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. Cancer Res. 75 446–455. 10.1158/0008-5472.CAN-14-122325432176 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="48559" pm="."><plain>KornakiewiczA.SolarekW.BieleckaZ. </plain></SENT>
<SENT sid="48560" pm="."><plain>F.LianF.SzczylikC.CzarneckaA. </plain></SENT>
<SENT sid="48561" pm="."><plain>M. (2014). Mammalian target of rapamycin inhibitors resistance mechanisms in clear cell renal cell carcinoma. Curr. </plain></SENT>
<SENT sid="48562" pm="."><plain>Signal Transduct. </plain></SENT>
<SENT sid="48563" pm="."><plain>Ther. 8 210–218. 10.2174/157436240966614020622274625152703 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="48564" pm="."><plain>KoulH.HuhJ. </plain></SENT>
<SENT sid="48565" pm="."><plain>S.RoveK. </plain></SENT>
<SENT sid="48566" pm="."><plain>O.CromptonL.KoulS.MeachamR. </plain></SENT>
<SENT sid="48567" pm="."><plain>B. (2011). Molecular aspects of renal cell carcinoma: a review. Am. </plain></SENT>
<SENT sid="48568" pm="."><plain>J. </plain></SENT>
<SENT sid="48569" pm="."><plain>Cancer Res. 1 240–254.21969126 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="48570" pm="."><plain>KuciaM.RecaR.MiekusK.WanzeckJ.WojakowskiW.Janowska-WieczorekA. (2005). Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23 879–894. 10.1634/stemcells.2004-034215888687 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="48571" pm="."><plain>KulkarniA. </plain></SENT>
<SENT sid="48572" pm="."><plain>A.VijaykumarV. </plain></SENT>
<SENT sid="48573" pm="."><plain>E.NatarajanS. </plain></SENT>
<SENT sid="48574" pm="."><plain>K.SenguptaS.SabbisettiV. </plain></SENT>
<SENT sid="48575" pm="."><plain>S. (2016). Sustained inhibition of cMET-VEGFR2 signaling using liposome-mediated delivery increases efficacy and reduces toxicity in kidney cancer. Nanomedicine 12 1853–1861. 10.1016/j.nano.2016.04.00227084552 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="48576" pm="."><plain>LapidotT.KolletO. (2002). The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice. Leukemia 16 1992–2003. 10.1038/sj.leu.240268412357350 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="48577" pm="."><plain>LevitzkiA. (2013). Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu. </plain></SENT>
<SENT sid="48578" pm="."><plain>Rev. </plain></SENT>
<SENT sid="48579" pm="."><plain>Pharmacol. </plain></SENT>
<SENT sid="48580" pm="."><plain>Toxicol. 53 161–185. 10.1146/annurev-pharmtox-011112-14034123043437 </plain></SENT>
</text></ref><ref id="B66"><text><SENT sid="48581" pm="."><plain>LiW.WangQ.SuQ.MaD.AnC.MaL. (2014). Honokiol suppresses renal cancer cells’ metastasis via dual-blocking epithelial-mesenchymal transition and cancer stem cell properties through modulating miR-141/ZEB2 signaling. Mol. </plain></SENT>
<SENT sid="48582" pm="."><plain>Cells 37 383–388. 10.14348/molcells.2014.000924810210 </plain></SENT>
</text></ref><ref id="B67"><text><SENT sid="48583" pm="."><plain>LiX.HuangY.XiaJ.ChenN.WeiQ.LiX. (2011). CXCR4 expression in patients with high-risk locally advanced renal cell carcinoma can independently predict increased risk of disease progression and poor overall survival. Asian Pac. </plain></SENT>
<SENT sid="48584" pm="."><plain>J. </plain></SENT>
<SENT sid="48585" pm="."><plain>Cancer Prev. 12 3313–3318.22471472 </plain></SENT>
</text></ref><ref id="B68"><text><SENT sid="48586" pm="."><plain>LiX.MaX.ChenL.GuL.ZhangY.ZhangF. (2015). Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis. Sci. </plain></SENT>
<SENT sid="48587" pm="."><plain>Rep. 5:13157 10.1038/srep13157 </plain></SENT>
</text></ref><ref id="B69"><text><SENT sid="48588" pm="."><plain>LiaoA.WangW.SunD.JiangY.TianS.LiJ. (2015). Bone morphogenetic protein 2 mediates epithelial-mesenchymal transition via AKT and ERK signaling pathways in gastric cancer. Tumour Biol. 36 2773–2778. 10.1007/s13277-014-2901-125448881 </plain></SENT>
</text></ref><ref id="B70"><text><SENT sid="48589" pm="."><plain>LichnerZ.SalehC.SubramaniamV.SeivwrightA.Prud’hommeG. </plain></SENT>
<SENT sid="48590" pm="."><plain>J.YousefG. </plain></SENT>
<SENT sid="48591" pm="."><plain>M. (2015). miR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell properties. Oncotarget 6 5567–5581. 10.18632/oncotarget.190125011053 </plain></SENT>
</text></ref><ref id="B71"><text><SENT sid="48592" pm="."><plain>LimS. </plain></SENT>
<SENT sid="48593" pm="."><plain>D.YoungA. </plain></SENT>
<SENT sid="48594" pm="."><plain>N.PanerG. </plain></SENT>
<SENT sid="48595" pm="."><plain>P.AminM. </plain></SENT>
<SENT sid="48596" pm="."><plain>B. (2008). Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases. Virchows Arch. 452 49–55. 10.1007/s00428-007-0530-418026989 </plain></SENT>
</text></ref><ref id="B72"><text><SENT sid="48597" pm="."><plain>LinC. </plain></SENT>
<SENT sid="48598" pm="."><plain>J.LinY. </plain></SENT>
<SENT sid="48599" pm="."><plain>L.LuhF.YenY.ChenR. </plain></SENT>
<SENT sid="48600" pm="."><plain>M. (2016). Preclinical effects of CRLX101, an investigational camptothecin-containing nanoparticle drug conjugate, on treating glioblastoma multiforme via apoptosis and antiangiogenesis. Oncotarget 10.18632/oncotarget.9878 [Epub ahead of print]. </plain></SENT>
</text></ref><ref id="B73"><text><SENT sid="48601" pm="."><plain>LinY.YangZ.XuA.DongP.HuangY.LiuH. (2015). PIK3R1 negatively regulates the epithelial-mesenchymal transition and stem-like phenotype of renal cancer cells through the AKT/GSK3beta/CTNNB1 signaling pathway. Sci. </plain></SENT>
<SENT sid="48602" pm="."><plain>Rep. 5:8997 10.1038/srep08997 </plain></SENT>
</text></ref><ref id="B74"><text><SENT sid="48603" pm="."><plain>LindgrenD.BostromA. </plain></SENT>
<SENT sid="48604" pm="."><plain>K.NilssonK.HanssonJ.SjolundJ.MollerC. (2011). Isolation and characterization of progenitor-like cells from human renal proximal tubules. Am. </plain></SENT>
<SENT sid="48605" pm="."><plain>J. </plain></SENT>
<SENT sid="48606" pm="."><plain>Pathol. 178 828–837. 10.1016/j.ajpath.2010.10.02621281815 </plain></SENT>
</text></ref><ref id="B75"><text><SENT sid="48607" pm="."><plain>LiuC.TangD. </plain></SENT>
<SENT sid="48608" pm="."><plain>G. (2011). MicroRNA regulation of cancer stem cells. Cancer Res. 71 5950–5954. 10.1158/0008-5472.CAN-11-103521917736 </plain></SENT>
</text></ref><ref id="B76"><text><SENT sid="48609" pm="."><plain>LiuJ.BoonkaewB.AroraJ.MandavaS. </plain></SENT>
<SENT sid="48610" pm="."><plain>H.MaddoxM. </plain></SENT>
<SENT sid="48611" pm="."><plain>M.ChavaS. (2015a). Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma. J. Pharm. </plain></SENT>
<SENT sid="48613" pm="."><plain>Sci. 104 1187–1196. 10.1002/jps.2431825573425 </plain></SENT>
</text></ref><ref id="B77"><text><SENT sid="48614" pm="."><plain>LiuJ.BoonkaewB.MandavaS. </plain></SENT>
<SENT sid="48615" pm="."><plain>H.AroraJ.MaddoxM.ChavaS. (2015b). MP39-01 in vitro performance of sorafenib-loaded PLGA and liposome nanoparticles as a delivery system in the treatment of renal cell carcinoma. J. Urol. 193 e454–e455. 10.1016/j.juro.2015.02.751 </plain></SENT>
</text></ref><ref id="B78"><text><SENT sid="48617" pm="."><plain>LiuQ. </plain></SENT>
<SENT sid="48618" pm="."><plain>J.ShenH. </plain></SENT>
<SENT sid="48619" pm="."><plain>L.LinJ.XuX. </plain></SENT>
<SENT sid="48620" pm="."><plain>H.JiZ. </plain></SENT>
<SENT sid="48621" pm="."><plain>G.HanX. (2016). Synergistic roles of p53 and HIF1alpha in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways. Drug Des. </plain></SENT>
<SENT sid="48622" pm="."><plain>Dev. </plain></SENT>
<SENT sid="48623" pm="."><plain>Ther. 10 745–755. 10.2147/DDDT.S88779 </plain></SENT>
</text></ref><ref id="B79"><text><SENT sid="48624" pm="."><plain>LiuX.FanD. (2015). The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. Curr. </plain></SENT>
<SENT sid="48625" pm="."><plain>Pharm. </plain></SENT>
<SENT sid="48626" pm="."><plain>Des. 21 1279–1291. 10.2174/138161282166614121111561125506898 </plain></SENT>
</text></ref><ref id="B80"><text><SENT sid="48627" pm="."><plain>LjungbergB.CowanN. </plain></SENT>
<SENT sid="48628" pm="."><plain>C.HanburyD. </plain></SENT>
<SENT sid="48629" pm="."><plain>C.HoraM.KuczykM. </plain></SENT>
<SENT sid="48630" pm="."><plain>A.MerseburgerA. </plain></SENT>
<SENT sid="48631" pm="."><plain>S. (2010). EAU guidelines on renal cell carcinoma: the 2010 update. Eur. </plain></SENT>
<SENT sid="48632" pm="."><plain>Urol. 58 398–406. 10.1016/j.eururo.2010.06.03220633979 </plain></SENT>
</text></ref><ref id="B81"><text><SENT sid="48633" pm="."><plain>LuB.HuangX.MoJ.ZhaoW. (2016). Drug delivery using nanoparticles for cancer stem-like cell targeting. Front. </plain></SENT>
<SENT sid="48634" pm="."><plain>Pharmacol. 7:84 10.3389/fphar.2016.00084 </plain></SENT>
</text></ref><ref id="B82"><text><SENT sid="48635" pm="."><plain>LyakhovichA.LleonartM. </plain></SENT>
<SENT sid="48636" pm="."><plain>E. (2016). Bypassing mechanisms of mitochondria-mediated cancer stem cells resistance to chemo- and radiotherapy. Oxid. </plain></SENT>
<SENT sid="48637" pm="."><plain>Med. </plain></SENT>
<SENT sid="48638" pm="."><plain>Cell. </plain></SENT>
<SENT sid="48639" pm="."><plain>Longev. 2016:1716341 10.1155/2016/1716341 </plain></SENT>
</text></ref><ref id="B83"><text><SENT sid="48640" pm="."><plain>MaC.KomoharaY.OhnishiK.ShimojiT.KuwaharaN.SakumuraY. (2016). Infiltration of tumor-associated macrophages is involved in CD44 expression in clear cell renal cell carcinoma. Cancer Sci. 107 700–707. 10.1111/cas.1291726918621 </plain></SENT>
</text></ref><ref id="B84"><text><SENT sid="48641" pm="."><plain>MaishiN.OhgaN.HidaY.AkiyamaK.KitayamaK.OsawaT. (2012). CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathol. </plain></SENT>
<SENT sid="48642" pm="."><plain>Int. 62 309–317. 10.1111/j.1440-1827.2012.02792.x22524658 </plain></SENT>
</text></ref><ref id="B85"><text><SENT sid="48643" pm="."><plain>McKayR. </plain></SENT>
<SENT sid="48644" pm="."><plain>R.De VelascoG.WernerL.BellmuntJ.HarshmanL.SweeneyC. (2016). A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. Cancer 122 2389–2398. 10.1002/cncr.3005627198170 </plain></SENT>
</text></ref><ref id="B86"><text><SENT sid="48645" pm="."><plain>MeltonC.JudsonR. </plain></SENT>
<SENT sid="48646" pm="."><plain>L.BlellochR. (2010). Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 463 621–626. 10.1038/nature0872520054295 </plain></SENT>
</text></ref><ref id="B87"><text><SENT sid="48647" pm="."><plain>MicucciC.MatacchioneG.ValliD.OrciariS.CatalanoA. (2015). HIF2alpha is involved in the expansion of CXCR4-positive cancer stem-like cells in renal cell carcinoma. Br. </plain></SENT>
<SENT sid="48648" pm="."><plain>J. </plain></SENT>
<SENT sid="48649" pm="."><plain>Cancer 113 1178–1185. 10.1038/bjc.2015.33826439684 </plain></SENT>
</text></ref><ref id="B88"><text><SENT sid="48650" pm="."><plain>MitsuiY.HirataH.ArichiN.HirakiM.YasumotoH.ChangI. (2015). Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways. Oncotarget 6 9577–9591. 10.18632/oncotarget.344525797254 </plain></SENT>
</text></ref><ref id="B89"><text><SENT sid="48651" pm="."><plain>MotzerR. </plain></SENT>
<SENT sid="48652" pm="."><plain>J.EscudierB.OudardS.HutsonT. </plain></SENT>
<SENT sid="48653" pm="."><plain>E.PortaC.BracardaS. (2008). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 449–456. 10.1016/S0140-6736(08)61039-918653228 </plain></SENT>
</text></ref><ref id="B90"><text><SENT sid="48654" pm="."><plain>MukherjeeD.ZhaoJ. (2013). The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am. </plain></SENT>
<SENT sid="48655" pm="."><plain>J. </plain></SENT>
<SENT sid="48656" pm="."><plain>Cancer Res. 3 46–57.23359227 </plain></SENT>
</text></ref><ref id="B91"><text><SENT sid="48657" pm="."><plain>MungerW.DeJoyS. </plain></SENT>
<SENT sid="48658" pm="."><plain>Q.JeyaseelanR. </plain></SENT>
<SENT sid="48659" pm="."><plain>Sr.TorleyL. </plain></SENT>
<SENT sid="48660" pm="."><plain>W.GrabsteinK. </plain></SENT>
<SENT sid="48661" pm="."><plain>H.EisenmannJ. (1995). Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell. </plain></SENT>
<SENT sid="48662" pm="."><plain>Immunol. 165 289–293. 10.1006/cimm.1995.12167553894 </plain></SENT>
</text></ref><ref id="B92"><text><SENT sid="48663" pm="."><plain>NegrierS. (2008). Temsirolimus in metastatic renal cell carcinoma. Ann. </plain></SENT>
<SENT sid="48664" pm="."><plain>Oncol. 19 1369–1370. 10.1093/annonc/mdn37318504249 </plain></SENT>
</text></ref><ref id="B93"><text><SENT sid="48665" pm="."><plain>NishizawaS.HirohashiY.TorigoeT.TakahashiA.TamuraY.MoriT. (2012). HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res. 72 2844–2854. 10.1158/0008-5472.CAN-11-306222552285 </plain></SENT>
</text></ref><ref id="B94"><text><SENT sid="48666" pm="."><plain>PattabiramanD. </plain></SENT>
<SENT sid="48667" pm="."><plain>R.WeinbergR. </plain></SENT>
<SENT sid="48668" pm="."><plain>A. (2014). Tackling the cancer stem cells – what challenges do they pose? Nat. </plain></SENT>
<SENT sid="48669" pm="."><plain>Rev. </plain></SENT>
<SENT sid="48670" pm="."><plain>Drug Discov. 13 497–512. 10.1038/nrd425324981363 </plain></SENT>
</text></ref><ref id="B95"><text><SENT sid="48671" pm="."><plain>PetroccaF.VecchioneA.CroceC. </plain></SENT>
<SENT sid="48672" pm="."><plain>M. (2008). Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 68 8191–8194. 10.1158/0008-5472.CAN-08-176818922889 </plain></SENT>
</text></ref><ref id="B96"><text><SENT sid="48673" pm="."><plain>Pode-ShakkedN.ShukrunR.Mark-DanieliM.TsvetkovP.BaharS.Pri-ChenS. (2013). The isolation and characterization of renal cancer initiating cells from human Wilms’ tumour xenografts unveils new therapeutic targets. EMBO Mol. </plain></SENT>
<SENT sid="48674" pm="."><plain>Med. 5 18–37. 10.1002/emmm.20120151623239665 </plain></SENT>
</text></ref><ref id="B97"><text><SENT sid="48675" pm="."><plain>PontaH.ShermanL.HerrlichP. </plain></SENT>
<SENT sid="48676" pm="."><plain>A. (2003). CD44: from adhesion molecules to signalling regulators. Nat. </plain></SENT>
<SENT sid="48677" pm="."><plain>Rev. </plain></SENT>
<SENT sid="48678" pm="."><plain>Mol. </plain></SENT>
<SENT sid="48679" pm="."><plain>Cell Biol. 4 33–45. 10.1038/nrm100412511867 </plain></SENT>
</text></ref><ref id="B98"><text><SENT sid="48680" pm="."><plain>PortellaL.VitaleR.De LucaS.D’AlterioC.IeranoC.NapolitanoM. (2013). Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS ONE 8:e74548 10.1371/journal.pone.0074548 </plain></SENT>
</text></ref><ref id="B99"><text><SENT sid="48681" pm="."><plain>QiX.YuD.JiaB.JinC.LiuX.ZhaoX. (2016). Targeting CD133(+) laryngeal carcinoma cells with chemotherapeutic drugs and siRNA against ABCG2 mediated by thermo/pH-sensitive mesoporous silica nanoparticles. Tumour Biol. 37 2209–2217. 10.1007/s13277-015-4007-926353857 </plain></SENT>
</text></ref><ref id="B100"><text><SENT sid="48682" pm="."><plain>RiniB. </plain></SENT>
<SENT sid="48683" pm="."><plain>I.BellmuntJ.ClancyJ.WangK.NiethammerA. </plain></SENT>
<SENT sid="48684" pm="."><plain>G.HariharanS. (2014). Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. </plain></SENT>
<SENT sid="48686" pm="."><plain>Oncol. 32 752–759. 10.1200/JCO.2013.50.530524297945 </plain></SENT>
</text></ref><ref id="B101"><text><SENT sid="48687" pm="."><plain>RonconiE.SagrinatiC.AngelottiM. </plain></SENT>
<SENT sid="48688" pm="."><plain>L.LazzeriE.MazzinghiB.BalleriniL. (2009). Regeneration of glomerular podocytes by human renal progenitors. J. Am. </plain></SENT>
<SENT sid="48690" pm="."><plain>Soc. </plain></SENT>
<SENT sid="48691" pm="."><plain>Nephrol. 20 322–332. 10.1681/ASN.200807070919092120 </plain></SENT>
</text></ref><ref id="B102"><text><SENT sid="48692" pm="."><plain>RosenL. </plain></SENT>
<SENT sid="48693" pm="."><plain>S.GordonM. </plain></SENT>
<SENT sid="48694" pm="."><plain>S.RobertF.MateiD. </plain></SENT>
<SENT sid="48695" pm="."><plain>E. (2014). Endoglin for targeted cancer treatment. Curr. </plain></SENT>
<SENT sid="48696" pm="."><plain>Oncol. </plain></SENT>
<SENT sid="48697" pm="."><plain>Rep 16:365 10.1007/s11912-013-0365-x </plain></SENT>
</text></ref><ref id="B103"><text><SENT sid="48698" pm="."><plain>RosenL. </plain></SENT>
<SENT sid="48699" pm="."><plain>S.HurwitzH. </plain></SENT>
<SENT sid="48700" pm="."><plain>I.WongM. </plain></SENT>
<SENT sid="48701" pm="."><plain>K.GoldmanJ.MendelsonD. </plain></SENT>
<SENT sid="48702" pm="."><plain>S.FiggW. </plain></SENT>
<SENT sid="48703" pm="."><plain>D. (2012). A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer. Clin. </plain></SENT>
<SENT sid="48704" pm="."><plain>Cancer Res. 18 4820–4829. 10.1158/1078-0432.CCR-12-009822767667 </plain></SENT>
</text></ref><ref id="B104"><text><SENT sid="48705" pm="."><plain>SagrinatiC.NettiG. </plain></SENT>
<SENT sid="48706" pm="."><plain>S.MazzinghiB.LazzeriE.LiottaF.FrosaliF. (2006). Isolation and characterization of multipotent progenitor cells from the Bowman’s capsule of adult human kidneys. J. Am. </plain></SENT>
<SENT sid="48708" pm="."><plain>Soc. </plain></SENT>
<SENT sid="48709" pm="."><plain>Nephrol. 17 2443–2456. 10.1681/ASN.200601008916885410 </plain></SENT>
</text></ref><ref id="B105"><text><SENT sid="48710" pm="."><plain>SamiA.KarsyM. (2013). Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumour Biol. 34 1991–2002. 10.1007/s13277-013-0800-523625692 </plain></SENT>
</text></ref><ref id="B106"><text><SENT sid="48711" pm="."><plain>SandlundJ.HedbergY.BerghA.GrankvistK.LjungbergB.RasmusonT. (2006). Endoglin (CD105) expression in human renal cell carcinoma. BJU Int. 97 706–710. 10.1111/j.1464-410X.2006.06006.x16536758 </plain></SENT>
</text></ref><ref id="B107"><text><SENT sid="48712" pm="."><plain>SchieberM. </plain></SENT>
<SENT sid="48713" pm="."><plain>S.ChandelN. </plain></SENT>
<SENT sid="48714" pm="."><plain>S. (2013). ROS links glucose metabolism to breast cancer stem cell and EMT phenotype. Cancer Cell 23 265–267. 10.1016/j.ccr.2013.02.02123518342 </plain></SENT>
</text></ref><ref id="B108"><text><SENT sid="48715" pm="."><plain>SehlM. </plain></SENT>
<SENT sid="48716" pm="."><plain>E.SinsheimerJ. </plain></SENT>
<SENT sid="48717" pm="."><plain>S.ZhouH.LangeK. </plain></SENT>
<SENT sid="48718" pm="."><plain>L. (2009). Differential destruction of stem cells: implications for targeted cancer stem cell therapy. Cancer Res. 69 9481–9489. 10.1158/0008-5472.CAN-09-207019996291 </plain></SENT>
</text></ref><ref id="B109"><text><SENT sid="48719" pm="."><plain>SeonB. </plain></SENT>
<SENT sid="48720" pm="."><plain>K.HabaA.MatsunoF.TakahashiN.TsujieM.SheX. (2011). Endoglin-targeted cancer therapy. Curr. </plain></SENT>
<SENT sid="48721" pm="."><plain>Drug Deliv. 8 135–143. 10.2174/15672011179366357021034418 </plain></SENT>
</text></ref><ref id="B110"><text><SENT sid="48722" pm="."><plain>SharmaN.NantaR.SharmaJ.GunewardenaS.SinghK. </plain></SENT>
<SENT sid="48723" pm="."><plain>P.ShankarS. (2015). PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget 6 32039–32060. 10.18632/oncotarget.505526451606 </plain></SENT>
</text></ref><ref id="B111"><text><SENT sid="48724" pm="."><plain>ShimonoY.MukohyamaJ.NakamuraS.MinamiH. (2015). MicroRNA regulation of human breast cancer stem cells. J. Clin. </plain></SENT>
<SENT sid="48726" pm="."><plain>Med. 5:E2 10.3390/jcm5010002 </plain></SENT>
</text></ref><ref id="B112"><text><SENT sid="48727" pm="."><plain>ShinozakiM.HirahashiJ.LebedevaT.LiewF. </plain></SENT>
<SENT sid="48728" pm="."><plain>Y.SalantD. </plain></SENT>
<SENT sid="48729" pm="."><plain>J.MaronR. (2002). IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J. Clin. </plain></SENT>
<SENT sid="48731" pm="."><plain>Invest. 109 951–960. 10.1172/JCI021457411927622 </plain></SENT>
</text></ref><ref id="B113"><text><SENT sid="48732" pm="."><plain>ShukrunR.ShakkedN. </plain></SENT>
<SENT sid="48733" pm="."><plain>P.DekelB. (2014). Targeted therapy aimed at cancer stem cells: Wilms’ tumor as an example. Pediatr. </plain></SENT>
<SENT sid="48734" pm="."><plain>Nephrol. 29 815–823. 10.1007/s00467-013-2501-023760992 </plain></SENT>
</text></ref><ref id="B114"><text><SENT sid="48735" pm="."><plain>SiegelR. </plain></SENT>
<SENT sid="48736" pm="."><plain>L.MillerK. </plain></SENT>
<SENT sid="48737" pm="."><plain>D.JemalA. (2015). Cancer statistics, 2015. CA Cancer J. Clin. 65 5–29. 10.3322/caac.2131425559415 </plain></SENT>
</text></ref><ref id="B115"><text><SENT sid="48739" pm="."><plain>SmithK. </plain></SENT>
<SENT sid="48740" pm="."><plain>M.DattiA.FujitaniM.GrinshteinN.ZhangL.MorozovaO. (2010). Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol. </plain></SENT>
<SENT sid="48741" pm="."><plain>Med. 2 371–384. 10.1002/emmm.20100009320721990 </plain></SENT>
</text></ref><ref id="B116"><text><SENT sid="48742" pm="."><plain>SteelJ. </plain></SENT>
<SENT sid="48743" pm="."><plain>C.WaldmannT. </plain></SENT>
<SENT sid="48744" pm="."><plain>A.MorrisJ. </plain></SENT>
<SENT sid="48745" pm="."><plain>C. (2012). Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. </plain></SENT>
<SENT sid="48746" pm="."><plain>Sci. 33 35–41. 10.1016/j.tips.2011.09.00422032984 </plain></SENT>
</text></ref><ref id="B117"><text><SENT sid="48747" pm="."><plain>SternbergC. </plain></SENT>
<SENT sid="48748" pm="."><plain>N.CalabroF.BracardaS.CarteniG.Lo ReG.RuggeriE. </plain></SENT>
<SENT sid="48749" pm="."><plain>M. (2015). Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial. Oncology 88 273–280. 10.1159/00036925625592399 </plain></SENT>
</text></ref><ref id="B118"><text><SENT sid="48750" pm="."><plain>SumitomoM.KoizumiF.AsanoT.HoriguchiA.ItoK.AsanoT. (2008). Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. Cancer Res. 68 1631–1635. 10.1158/0008-5472.CAN-07-653218339841 </plain></SENT>
</text></ref><ref id="B119"><text><SENT sid="48751" pm="."><plain>TooleB. </plain></SENT>
<SENT sid="48752" pm="."><plain>P. (2009). Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin. </plain></SENT>
<SENT sid="48753" pm="."><plain>Cancer Res. 15 7462–7468. 10.1158/1078-0432.CCR-09-047920008845 </plain></SENT>
</text></ref><ref id="B120"><text><SENT sid="48754" pm="."><plain>TrinderP.SeitzerU.GerdesJ.SeligerB.MaeurerM. (1999). Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer. Int. </plain></SENT>
<SENT sid="48755" pm="."><plain>J. </plain></SENT>
<SENT sid="48756" pm="."><plain>Oncol. 14 23–31.9863005 </plain></SENT>
</text></ref><ref id="B121"><text><SENT sid="48757" pm="."><plain>UedaK.OgasawaraS.AkibaJ.NakayamaM.TodorokiK.UedaK. (2013). Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLoS ONE 8:e75463 10.1371/journal.pone.0075463 </plain></SENT>
</text></ref><ref id="B122"><text><SENT sid="48758" pm="."><plain>VermaS.MilesD.GianniL.KropI. </plain></SENT>
<SENT sid="48759" pm="."><plain>E.WelslauM.BaselgaJ. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. </plain></SENT>
<SENT sid="48761" pm="."><plain>J. </plain></SENT>
<SENT sid="48762" pm="."><plain>Med. 367 1783–1791. 10.1056/NEJMoa120912423020162 </plain></SENT>
</text></ref><ref id="B123"><text><SENT sid="48763" pm="."><plain>VilarE.Perez-GarciaJ.TaberneroJ. (2011). Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol. </plain></SENT>
<SENT sid="48764" pm="."><plain>Cancer Ther. 10 395–403. 10.1158/1535-7163.MCT-10-090521216931 </plain></SENT>
</text></ref><ref id="B124"><text><SENT sid="48765" pm="."><plain>VisvaderJ. </plain></SENT>
<SENT sid="48766" pm="."><plain>E.LindemanG. </plain></SENT>
<SENT sid="48767" pm="."><plain>J. (2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. </plain></SENT>
<SENT sid="48768" pm="."><plain>Rev. </plain></SENT>
<SENT sid="48769" pm="."><plain>Cancer 8 755–768. 10.1038/nrc249918784658 </plain></SENT>
</text></ref><ref id="B125"><text><SENT sid="48770" pm="."><plain>WaldmannT. </plain></SENT>
<SENT sid="48771" pm="."><plain>A. (2014). Interleukin-15 in the treatment of cancer. Expert Rev. </plain></SENT>
<SENT sid="48772" pm="."><plain>Clin. </plain></SENT>
<SENT sid="48773" pm="."><plain>Immunol. 10 1689–1701. 10.1586/1744666X.2014.97385625359408 </plain></SENT>
</text></ref><ref id="B126"><text><SENT sid="48774" pm="."><plain>WaldmannT. </plain></SENT>
<SENT sid="48775" pm="."><plain>A.LugliE.RoedererM.PereraL. </plain></SENT>
<SENT sid="48776" pm="."><plain>P.SmedleyJ. </plain></SENT>
<SENT sid="48777" pm="."><plain>V.MacallisterR. </plain></SENT>
<SENT sid="48778" pm="."><plain>P. (2011). Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood 117 4787–4795. 10.1182/blood-2010-10-31145621385847 </plain></SENT>
</text></ref><ref id="B127"><text><SENT sid="48779" pm="."><plain>WangL.ChenW.GaoL.YangQ.LiuB.WuZ. (2012a). High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J. Surg. </plain></SENT>
<SENT sid="48781" pm="."><plain>Oncol. 10:212 10.1186/1477-7819-10-212 </plain></SENT>
</text></ref><ref id="B128"><text><SENT sid="48782" pm="."><plain>WangL.HuangT.ChenW.GaoX.ZhouT.WuZ. (2012b). Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells. Oncol. </plain></SENT>
<SENT sid="48783" pm="."><plain>Rep. 28 2043–2048. 10.3892/or.2012.202822972438 </plain></SENT>
</text></ref><ref id="B129"><text><SENT sid="48784" pm="."><plain>WangL.ParkP.La MarcaF.ThanK. </plain></SENT>
<SENT sid="48785" pm="."><plain>D.LinC. </plain></SENT>
<SENT sid="48786" pm="."><plain>Y. (2015). BMP-2 inhibits tumor-initiating ability in human renal cancer stem cells and induces bone formation. J. Cancer Res. </plain></SENT>
<SENT sid="48788" pm="."><plain>Clin. </plain></SENT>
<SENT sid="48789" pm="."><plain>Oncol. 141 1013–1024. 10.1007/s00432-014-1883-025431339 </plain></SENT>
</text></ref><ref id="B130"><text><SENT sid="48790" pm="."><plain>WangL.ParkP.ZhangH.La MarcaF.ClaesonA.ThanK. (2012c). BMP-2 inhibits tumor growth of human renal cell carcinoma and induces bone formation. Int. </plain></SENT>
<SENT sid="48791" pm="."><plain>J. </plain></SENT>
<SENT sid="48792" pm="."><plain>Cancer 131 1941–1950. 10.1002/ijc.2744422275155 </plain></SENT>
</text></ref><ref id="B131"><text><SENT sid="48793" pm="."><plain>WeitzenfeldP.Ben-BaruchA. (2014). The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett. 352 36–53. 10.1016/j.canlet.2013.10.00624141062 </plain></SENT>
</text></ref><ref id="B132"><text><SENT sid="48794" pm="."><plain>WeygantN.QuD.MayR.TierneyR. </plain></SENT>
<SENT sid="48795" pm="."><plain>M.BerryW. </plain></SENT>
<SENT sid="48796" pm="."><plain>L.ZhaoL. (2015). DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma. Oncotarget 6 2193–2205. 10.18632/oncotarget.305925605241 </plain></SENT>
</text></ref><ref id="B133"><text><SENT sid="48797" pm="."><plain>XiaP.XuX. </plain></SENT>
<SENT sid="48798" pm="."><plain>Y. (2015). PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application. Am. </plain></SENT>
<SENT sid="48799" pm="."><plain>J. </plain></SENT>
<SENT sid="48800" pm="."><plain>Cancer Res. 5 1602–1609.26175931 </plain></SENT>
</text></ref><ref id="B134"><text><SENT sid="48801" pm="."><plain>YamashitaM.HirohashiY.TorigoeT.KusumotoH.MuraiA.ImagawaT. (2016). Dnajb8, a member of the heat shock protein 40 family has a role in the tumor initiation and resistance to docetaxel but is dispensable for stress response. PLoS ONE 11:e0146501 10.1371/journal.pone.0146501 </plain></SENT>
</text></ref><ref id="B135"><text><SENT sid="48802" pm="."><plain>YangC.ZhangY.ZhangY.ZhangZ.PengJ.LiZ. (2015). Downregulation of cancer stem cell properties via mTOR signaling pathway inhibition by rapamycin in nasopharyngeal carcinoma. Int. </plain></SENT>
<SENT sid="48803" pm="."><plain>J. </plain></SENT>
<SENT sid="48804" pm="."><plain>Oncol. 47 909–917. 10.3892/ijo.2015.310026202311 </plain></SENT>
</text></ref><ref id="B136"><text><SENT sid="48805" pm="."><plain>YangZ. </plain></SENT>
<SENT sid="48806" pm="."><plain>J.Wechsler-ReyaR. </plain></SENT>
<SENT sid="48807" pm="."><plain>J. (2007). Hit ‘em where they live: targeting the cancer stem cell niche. Cancer Cell 11 3–5. 10.1016/j.ccr.2006.12.00717222787 </plain></SENT>
</text></ref><ref id="B137"><text><SENT sid="48808" pm="."><plain>YeS.ParkB. </plain></SENT>
<SENT sid="48809" pm="."><plain>H.SongK. </plain></SENT>
<SENT sid="48810" pm="."><plain>J.KimJ. </plain></SENT>
<SENT sid="48811" pm="."><plain>R.JangK. </plain></SENT>
<SENT sid="48812" pm="."><plain>Y.ParkH. </plain></SENT>
<SENT sid="48813" pm="."><plain>S. (2013). In vivo inhibition of bone morphogenetic protein-2 on breast cancer cell growth. Spine (Phila Pa 1976) 38 E143–E150. 10.1097/BRS.0b013e31827db4c623169070 </plain></SENT>
</text></ref><ref id="B138"><text><SENT sid="48814" pm="."><plain>YilmazO. </plain></SENT>
<SENT sid="48815" pm="."><plain>H.ValdezR.TheisenB. </plain></SENT>
<SENT sid="48816" pm="."><plain>K.GuoW.FergusonD. </plain></SENT>
<SENT sid="48817" pm="."><plain>O.WuH. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441 475–482. 10.1038/nature0470316598206 </plain></SENT>
</text></ref><ref id="B139"><text><SENT sid="48818" pm="."><plain>ZhangY.ChenX.QiaoM.ZhangB. </plain></SENT>
<SENT sid="48819" pm="."><plain>Q.WangN.ZhangZ. (2014). Bone morphogenetic protein 2 inhibits the proliferation and growth of human colorectal cancer cells. Oncol. </plain></SENT>
<SENT sid="48820" pm="."><plain>Rep. 32 1013–1020. 10.3892/or.2014.330824993644 </plain></SENT>
</text></ref><ref id="B140"><text><SENT sid="48821" pm="."><plain>ZhangY.SunB.ZhaoX.LiuZ.WangX.YaoX. (2013). Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J. Surg. </plain></SENT>
<SENT sid="48823" pm="."><plain>Oncol. 108 414–419. 10.1002/jso.2340223996537 </plain></SENT>
</text></ref><ref id="B141"><text><SENT sid="48824" pm="."><plain>ZhangY. </plain></SENT>
<SENT sid="48825" pm="."><plain>J.DuanY.ZhengX. </plain></SENT>
<SENT sid="48826" pm="."><plain>F. (2011). Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov. </plain></SENT>
<SENT sid="48827" pm="."><plain>Today 16 325–331. 10.1016/j.drudis.2011.02.00821333749 </plain></SENT>
</text></ref><ref id="B142"><text><SENT sid="48828" pm="."><plain>ZhengY.WangX.WangH.YanW.ZhangQ.ChangX. (2014). Bone morphogenetic protein 2 inhibits hepatocellular carcinoma growth and migration through downregulation of the PI3K/AKT pathway. Tumor Biol. 35 5189–5198. 10.1007/s13277-014-1673-y </plain></SENT>
</text></ref><ref id="B143"><text><SENT sid="48829" pm="."><plain>ZhuY.ZhangX.LiuY.ZhangS.LiuJ.MaY. (2012). Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo. Tumour Biol. 33 1349–1362. 10.1007/s13277-012-0383-622492237 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
